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The effect of a single ALG preparation given 011 days -k and -2
prior to antigen on the primary humoral immune responses of six mouse
strains against different doses of sheep erythrocytes (SRBC), and
type III pneumococcal polysaccharide (SSS-IIl) was tested. The
effect of the same ALG preparation on the secondary humoral immune
response of the same mouse strains was also examined, and in a
limited number of experiments the antibody production in different
immunoglobulin classes and subclasses was also measured. In addition,
the effect of several other ALG preparations on the primary response
against a standard dose of the above antigens as well as against
bovine serum albumin (BSA) was also tested in selected mouse strains.
These preparations were either obtained from a single horse at
different stages of immunization or from different horses. In
addition to the standard schedule the effect of an alternative protocol
(day 0) on the immune response to SSS-III was also investigated in
Balb/c mice. In a single experiment the anti-SSS-III response of
ALG-treated CBA mice reconstituted with various lymphoid cells was
also measured. Finally the immune responses of different mouse
strains against SRBC, SSS-III and BSA were determined.
The results indicate that the ALG mainly used in the
bulk of the studies suppressed the immune response of all six
mouse strains against all the doses of the three antigens tested.
It also suppressed the secondary responses of these strains to SRBC.
This effect was also generally apparent in various immunoglobulin
subclasses. However, in some cases, the response in certain
immunoglobulin subclasses was enhanced or unaffected.
The other ALG preparations raised in different horses also
suppressed the primary responses against SRBC and BSA, although their
effect on anti-SSS-III response was variable. The results obtained
with different ALG preparations obtained from the same horse at
different stages of immunization suggest that IgG responses are
generally more susceptible to ALG treatment than the IgM responses,
and that ALG can suppress the thymus dependent responses more
readily than the thymus independent ones.
The results of two ALG treatment schedules indicate that the
ability of ALG to suppress at least anti-SSS-III response may largely
depend on the time of its administration. Thus most of the ALG
preparations were ineffective when given on the same day as SSS-III.
The response of ALG-treated and reconstituted mice (in one
experiment) suggests that the impaired response of the ALG-treated
mice to SSS-III may be partially restored by bone marrow, spleen
or thymus cells.
The results of the measurement of humoral immune responses in
different mouse strains indicate that significant inter-strain
variation may exist in the magnitude of the primary immune responses
to different antigens.
The /
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The results of these studies have been discussed in the light
of the present knowledge of the biological properties of anti-
lymphocyte serum, the thymus dependence of different immune responses
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The effect of a single ALG preparation given on days
-k and -2 prior to antigen on the primary humoral immune
responses of six mouse strains against different doses of
sheep erythrocytes (SRBC), and type III pneumococcal
polysaccharide (SSS-III) was tested. The effect of the
same ALG preparation on the secondary humoral immune response
of the same mouse strains was also examined, and in a limited
number of experiments the antibody production in different
immunoglobulin classes and subclasses was also measured.
In addition, the effect of several other ALG preparations
on the primary response against a standard dose of the above
antigens as well as against bovine serum albumin (BSA) was
also tested in selected mouse strains. These preparations
were either obtained from a single horse at different stages
of immunization or from different horses. In addition to
the standard schedule the effect of an alternative protocol
(day 0) on the immune response to SSS-III was also investigated
in Balb/c mice. In a single experiment the anti-SSS-III
response of ALG-treated CBA mice reconstituted with various
lymphoid cells was also measured. Finally the Immune
responses of different mouse strains against SRBC, SSS-III
and BSA were determined.
The results indicate that the ALG mainly used in the
bulk of the studies suppressed the immune response of all
(ii)
six souse strains against all the doses of the three antigens
tested. It also suppressed the secondary responses of these
strains to SRBC. This effect was also generally apparent
in various immunoglobulin subclasses. However, in some
cases, the response in certain inanunoglobulin subclasses
was enhanced or unaffected.
The other ALG preparations raised in different horses
also suppressed the primary responses against SRBC and BSA,
although their effect on anti-SSS-III response was variable.
The results obtained with different ALG preparations obtained
from the same horse at different stages of immunization
suggest that IgG responses are generally more susceptible
to ALG treatment than the IgM responses, and that ALG can
suppress the thymus dependent responses more readily than
the thymus independent ones.
The results of two ALG treatment schedules indicate
that the ability of ALG to suppress at least anti-SSS-III
response may largely depend on the time of its administration.
Thus most of the ALG preparations were ineffective when given
on the same day as SSS-III.
The response of ALG-treated and reconstituted mice
(in one experiment) suggests that the impaired response of
the ALG-treated mice to SSS-III may be partially restored
by bone marrow, spleen or thymus cells.
The results of the measurement of humoral immune
responses in different mouse strains indicate that significant
(iii)
inter-strain variation may exist in the magnitude of the
primary immune responses to different antigens.
The results of these studies have been discussed in
the light of the present knowledge of the biological
properties of anti-lymphocyte serum, the thymus dependence
of different immune responses and the mechanism of immune
reactions.
(iv)
PURPOSE OP THE STUDY
Detailed investigations undertaken in the last few
years have unequivocally established the efficacy of
anti-lymphocytic globulins as potent inaaunosuppressive
agents. Their ability to suppress cell mediated immune
responses has been well documented in a variety of experi¬
mental models (James, 19'>7&» 19-j9» Madavar, 1909? Sell,
19o9? Lance, 1970c? Taub, 1970? Joost, 1970? Rolland
and Nairn, 1972). However, their effect on humoral immune
response has been less consistent, being influenced by
various factors including the time of antigen administration,
the nature of the antigen under test, the dose of the antigen,
the incorporation of tho antigen into adjuvants, and the
strains of animals used. This inconsistency has given
rise to conflicting views on the ability of anti-lyiaphocytic
antibody to suppress humoral immune responses and has also
led on occasions to the dangerous assumption that this
reagent may not affect humoral immune responses.
In order to clarify this situation it was decided to
determine the effect of anti-lymphocytic antibody on the
humoral immune responses of a number of strains of mice
against sheep erythrocytes, pneumococcal polysaccharide
and bovine serum albumin.
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INTRODUCTION
MECHANISM OF IMMUNE RESPONSES
The era of experimental immunology probably began
with Jenner*8 classical experiments in 1798 in which he
observed that the dairymaids who were exposed to cowpox
virus were subsequently protected against smallpox virus
infections. This line of approach to immunity pursued
further by Pasteur and others ultimately formed the basis
of the present vaccination practice for protection against
infectious agents.
While by the end of the 19th century antibodies
were believed to be the active agents for conferring
immunity, a group of workers led by Metchnikoff were
more impressed with the efficiency of certain white
cells of blood and other body fluids to destroy bacteria.
However, with the efforts of Wri^tit and various other
workers during the late 19th and very early 20th centuries,
the two concepts were reconciled and it was accepted that
although it was phagocytes which engulfed and destroyed
bacteria, their activities were greatly assisted by the
attachment of antibodies to the bacterial surface (Wright,
1906).
Humoral immune response
The organs primarily involved in the establishment of
immunity following infection or antigen administration
have long been suspected to be the spleen and lymph nodes.
Concluding his lecture to the Harvey Society in 1907
Councilman clearly implied the association of the pro¬
liferative activity in lymphoid organs with the recovery
from infections and subsequent immunity (Councilman,
1907)* The sequence of events following immunization
involving extensive hyperplasia in various lymphoid
organs including the spleen, lymph nodes and the thymus
have since been documented by various authors (jEhrich,
1929? Conway, 1938). Furthermore, McMaster and Hudack
(1935) showed that the level of agglutinin extracted from
the regional lymph node following intradermal injection
of Salmonella was greater than that of non-regional node
or serum. Their findings were later confirmed by Shrich
and Harris (1942) and be Gara and Angevine (1943).
The first popular candidate among the cells of lymphoid
origin responsible for the production of antibody were
macrophages but during the 1920*s they were superceded in
popularity by lymphocytes. However, the latter too lost
ground following the observations of Ding and Plum (1937)
who reported a positive correlation between hypergamma¬
globulinemia and the increased plasmacytoais in the
spleen. Furthermore, Undritz (1938) produced additional
evidence on clinical grounds to connect plasma cells with
antibody production.
In experimental animals the observations of Bjorneboe
-3-
and Gormaen (1943) and Fagraeus (1943a,b) also suggested
an association between antibody production and plasma
cells. This association was further strengthened
following the development of radiolabelling and Immuno¬
fluorescence techniques which permitted the direct
demonstration of antibody on the cells of plasmacytic
series (Coons, Leduc and Connolly, 1953; Ortega and
Mellors, 1957; White, 19->3).
Delayed hypersensitivity
Another type of immunological reaction, which could
not be associated with any detectable circulating antibody
nor with the development of plasma cells was first
explored by Koch in the 1390»s. The classical example
of this type of immune response is the reaction of
tuberculosis patients to tubercle antigen, but it includes
contact dermatitis, sensitivity to chemicals and a number
of other allergic reactions. This aspect of immunology
did not receive much attention at the time but it is now
accepted that delayed hypersensitivity, which this
reaction was later termed, is an important part of the
defence mechanism and can be induced by a variety of
antigens.
In the 1930'» the phenomenon of delayed hyper¬
sensitivity was extensively studied by Landsteiner and
hie colleagues. They showed that contact sensitivity
to picryl chloride could be transferred from sensitized
to normal guinea pigs by taeans of peritoneal exudate cells
(Landsteiner and Chase, 1942). Later it was shown that
sensitivity to tuberculin could also be passively trans-
ferred in a similar way (Chase, 1945)• although earlier
attempts to transfer the reaction to non-sensitized
animals by means of serum from sensitized animals had been
unsuccessful (Zinsser and Mueller, 1925; Freund, 1926).
It was also shown that passive transfer of the tuberculin
reaction could be brought about by spleen or lymph node
cells as well as by the peritoneal cells from a sensitized
animal. The passive transfer of delayed hypersensitivity
by means of lymphoid cells has now been confirmed many
times (for example, Kirchheimer and Veiser, 19471
Stavitsky, 1948; Metaxas and Metaxas-Duhler, 1955; Turk,
1961).
Homograft immunity
It has long been known by surgeons that skin and
tissue grafts from one individual to another are not
normally accepted. The precise mechanism of rejection
and the factors influencing it are not yet very clearly
understood. There have been, however, a number of
studies of the morphological changes both within the
graft itself and within the regional lymph nodes.
Most of the early studies in transplantation were
•5
limited to the transfer of tumours in rodents. The
observations on the histology of regressing or rejected
tumour grafts indicated the implication of the lymphoid
tissue in the process of graft rejection (Jensen, 1903;
Ehrlich, 1906; Bashford, Murray and Cramer, 1908; Levin,
1910; Da Fanco, 1912). In a very comprehensive report
published in a monograph by Murphy in 1926, he emphasised
the role lymphocytes played in the rejection of tumour
grafts.
Fleisher (1917) implanted guinea pig kidney tissue
subcutaneously in sensitized rabbits and found that the
grafts soon underwent necrosis and the renal tissue
became heavily infiltrated with lymphocytes and poly¬
morphonuclear leucocytes. Similarly lymphocytic
infiltration was observed by Loeb (1918) when he grafted
thyroid tissue between guinea pigs.
The concept of genetically determined antigenic
factors responsible for the immunological reactions in
the host which eventually resulted in the rejection of
histoincompatible tissue was first reported by Gorer in
1938. This was later expanded by Medawar in the 1940*s
(Medawar, 1944, 1945* 1946a,b) and marked the beginning
of modern understanding of homograft reactions.
Mitchison (1953» 1954, 1955) demonstrated that
transplantation immunity to certain tumours could be
transferred to non-immune mice by injection with cells
from lymph nodes of tumour grafted mice. Dillingham and
his colleagues confirmed these results (Billingham, Brent
and Medawar, 1954) •
Role of the thymus in the immune response
The experiments reported by Miller (1961) showing
that neonatal thymectomy in mice prevented the proper
development of all cell mediated and some antibody
responses could perhaps be claimed to mark the modern
era of cellular immunology. An organ which hitherto
seemed to have no significant function, whose removal in
adult life had no apparently adverse consequences, acquired
a unique importance. Its removal shortly following birth
hampered the development of an entire population of
lymphocytes including those in the periarteriolar regions
of spleen and paracortical areas of lymph node, the
majority of those in the thoracic duct lymph and about
half of the peripheral blood population (Miller, 1962b;
Parrott and De Souaa, 19o6b). Following the initial
studies of Miller (1962b) and Parrott and East (1962),
it was soon recognized that neonatal thymectomy impaired
the insnune response against a variety of antigens. For
example it resulted in a reduced antibody response to
heterologous blood cells (Friedman, 1965* Sinclair, 1965;
Law, 1966; Taylor and Wortis, 1968; Lemel, Cooper and
Good, 1971; Dresser, 1972), heterologous serum proteins
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(Good, Dalinasso, Martinez, Archer, Pierce and Papermaater,
19o2; Jankovic, Vakaraan and Arnason, 1962; Arnason,
D© Vaux and Shaffner, 1964), bacterial antigens (Miller,
Marshall and White, 19^2; Arnason ejt al., 19o4| Had ley-
ami Elbers, 1964), viruses (East, Parrott, Cheatertnan
and Pomerance, 1963; Foldes, Szeri, Banos, Anderlik and
Balazs, 1964, 19^5; Allison and Taylor, 1967; Mori,
Tasaki, Kiciura and Takeya, 1967; Mori, Kimoto and Takeya,
1970; Cheville, 1970) and various other antigens (pahey,
Earth and Law, 19^5; Kruger and Gershon, 1971)• Further
studies also indicated that neonatal thymectomy alone or
adult thymectomy combined with radiation also impaired
the rejection of homografts (Miller, 1962a,b; Daltsasso,
Martinez and Good, 19o2; Davis, Tyan and Cole, 1964;
Sosin, Hilgard and Martinez, 1966; Weston, Carter,
Leuchars, Wallis and Davies, 1972) and the development of
delayed type hypersensitivity reactions to a variety of
agents (Arnason, Jankovic, Waksman arid Wennersten, 1962;
De Sousa and Parrott, 1969).
Since the development of techniques for selectively
eliminating •T* cells (Reif and Allen, 1964, 1966; Boyse,
Miyazawa, Aoki and Old, 1966; Raff, 1969; Schlesinger
and Yron, 19o9; Aoki, Haraaerling, dellarven, Boyse and
Old, 1969), and 'B* cells (Raff, Has© and Mitchison,
1971; hasten, Sprent and Miller, 1971; Miller, Sprent,
Basten and Warner, 1972) It has been possible to further
-8
establish the role of ,T* cells in antibody production
(Greaves and Moller, 1970? Raff, 1970; Schlesinger,
1970? Mitchison, 1971b; Miller and Sprent, 1971) and
homograft rejection and other cell mediated immune responses
(Miller, Brunner, Sprent, Russell and Mitchell, 1971?
Cantor, 1972? Sprent and Miller, 1972? Moller, 1971?
Rouse, R&linghoff and Warner, 1972),
Cell co-operation in immunity
Prom the findings of Miller and Good and his col¬
leagues (Good, Kelly, Rotstein and Varco, 19o2) in mammals
and those of Warner and Szeriberg (19o4) in the chicken
it became apparent that the lymphoid cell populations
could be divided into at least two compartments - one
which required to be processed by the thymus to gain
immunocompetence arid the other which did not require the
influence of thymus and which derived its origin from
bursa in the chicken or bone marrow in the mammal. The
former are popularly known as cells while the latter
have been designated •T-independent• or •B* cells (Roitt,
Greaves, Torrigiani, Brostoff and Playfair, 19o9)»
Using irradiated mice which were subsequently injected
with cells of thymic or bone marrow origin or both, to¬
gether with sheep erythrocytes, Clamon and his colleagues
showed that the number of antibody producing cells found
in the spleens of animals repopulated with thymus and bone
-9-
marrow cells were far greater than the sum of those
obtained when thymus or bone marrow cells alone were
given (daman. Chaperon and Triplet, 1966). This
increase in immunological response due to the synergistic
effect of the two cell populations is now connsonly known
as thymus—bone marrow co-operation. Other examples of
similar synergistic co-operative effects have been
demonstrated in immune responses against USA (Taylor,
19o9) and against haptens in conjunction with carriers
(Rajewsky, Schlrrmacher, Nase and Jerne, 1969; Mitchison,
1971a? Taylor and Iverson, 1971)• Furthermore, experi¬
mental results have been reported showing similar co¬
operative effects between thymic and marrow cells in the
cell mediated immune systems (Argyrls, 1968} Hilgard,
1970; Earchilon and Gershon, 1970; Trident, Biasi,
Chieco-Bianchi and Fiore-Bonati, 1971)*
Thymus dependence of immune responses
In the preceding sections it has been suggested that
the presence of thymus derived cells are essential to
initiate a humoral immune response to a variety of antigens.
Nevertheless, there are a variety of antigens which do
not require the imrticipation of *T* cells to initiate
an immune response (Humphrey, Parrot t and East, 19>*»;
Parrott and De Sousa, 1966a; Davles, Carter, Leuchars,
Vallis and Dietrich, 19->9; Kerbel and Eidenger, 1971;
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Feldraan and listen, 1971? Andersaon and Blumgren, 1971).
Moreover, In the case of the so called thymus-dependent
antigens, it has been reported that an increase in
antigen dose may overcome the need for the helper effect
of thymus derived cells (Sinclair and Elliott, 1968)
Taylor and Mortis, 1968) iyan, Herzenberg and Oibbs,
1969) Playfair and Purves, 1971? Haskill, Marbrook and
Elliott, 1971).
Nature of antibody producing cells
Although the presence of thymus, or cells of thymic
origin, are essential for tho production of antibody
against a number of antigens, the production of the anti¬
body itself is not physically carried out by these cells
(Davies, Leuchars, Vallis, Merchant and Elliott, 1967).
It would appear that the function of antibody production
is carried out by the bone marrow derived population of
plasma cells (Klein and Herzenburgh, 1967) Mitchell and
Miller, 1968) Noesal, Cunningham, Mitchell and Miller,
1968).
Role of macrophages
It has long been known that a large part of injected
antigen is taken up by macrophages, although the signific
ance of this uptake in relation to the initiation of
immune response has been the point of considerable debate
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However, the studies of Gallily and FeIdman in irradiated
animals indicated that the presence of a macrophage rich
population of peritoneal exudate cells was essential to
initiate an immune response in the irradiated recipient
of various lymphoid cells (Gallily and Feldman, 1966,
1967)* Similar observations supporting the importance
of macrophages in initiating an antibody response have
been reported by other workers using both in vivo and
in vitro experimental models (Hosier, 1967; Hoffman,
1970; Sabot and Foldman, 1970; Feldman and Palmer,
1971; Tan and Gordon, 1971; Askov and Halliday, 1971)•
Furthermore, the requirement of macrophages has also been
shown to be essential in various models of cell mediated
immune responses (liersh and Harris, 1968; Seeger and
Oppenheim, 1970; Lonai and Feldman, 1971)• However
there are certain antigens which have been shown to
initiate an immune response without the participation of
macrophages (shortman, Dlener, Russell and Armstrong,
1970; Feldman and Palmer, 1971).
Stem cells and their origin
It has been known for some time that the lethal
effects of radiation could be overcome by the administrat¬
ion of live haemupoietic ceils from various organs. The
principal role of the protective cell inoculum was found
to be to restore granulocyte, and platelet formation,
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although erythrocyte and lymphocyte production was also
restored, and these cell types were traced to be of the
donor bone marrow origin (Ford, Hamerton, Barnes and
Loutit, 195o)• It was also found that the best
restorative cells were bone marrow cells, while spleen
and peripheral blood cells were less effective and lymph
node and thymus cells were without any effect*
Utilizing the spleen colony forming assay, it was
shown that each colony arising following bone marrow
injection into irradiated animals was the product of a
single bone marrow cell and consisted of one type of cells,
i.e. erythropoietic, granulocytic or megakaryocytic.
However, if the cells from a single colony were subsequently
injected into a second host, they gave rise to colonies of
all three kinds. It was thus concluded that bone marrow
contained a pluripotential lymphocyte-like stem cell
(Cudkowicz, Bennet and Shearer, 19j4).
By the injection of chromosocially marked cells from
various sources and following their redistribution and
localization, it was found that thymus, spleen and lymph
node cells would settle in the spleen and lymph nodes,
but not in the thymus. But, by contrast some bono marrow
cells would colonize spleen, lymph nodes and thymus (Ford
and Micklem, 19^3? Micklem, Ford, Evans and Gray, 19t>&).
Furthermore in extreme cases a single cell has been known
to repopulate the entire lymphoid and liaemopoietic tissue
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of the body (Loutitf 19o5)» In summary, the bone marrow
seems to be the ultimate source of stem cells in the adult
animal, supplying the other haeraopoietic and lymphoid
organs.
In the preceding paragraphs, I have attempted to
summarize only briefly the development of various aspects
of immunology, and the present concept of cells involved
in immune responses. I have restricted myself only to
the aspects which are going to be essential for the under¬
standing of the work described in the following chapters
of this thesis. However, there are several recent
reviews on the role of various cells and cell interactions
in the immune response (Roitt, Greaves, Torrigiani,
Brostoff and Playfair, 19^9? Lischner and DiGeorge, 19^9?
Richter, 1970? Taylor and Xverson, 1970; Playfair, 1971?




Once the relationship between the cells of the
lymphoid system and immune response was established, it
seemed reasonable to use antisera against such cells to
suppress immune reactions. As early as 1899* when the
role of various lymphoid cells in iommnological responses
was only in the speculative stage, Metchnikoff, who
strongly believed that it was •white* cells of the blood
and other lymphoid tissues which were responsible for
immunity against bacterial infections, raised antisera
against rat or rabbit spleen and lymph node cells by
immunizing guinea pigs with a saline emulsified preparation.
These antisera showed leucoagglutinating and leucolytic
activities with a degree of species specificity but not
tissue specificity and reacted with polynuclear and mono¬
nuclear cells of rat as well as mast cells. He used
these antisera to lovor the resistance of its recipients
to infections (Metchnikoff, 1899). These observations
were followed by those of Besredka (1900) who showed that
the lympholytic activities of rabbit anti-guinea pig lymph
node sera were complement-dependent. He confirmed the
species specificity described by Metchnikoff and, further¬
more, indicated a small degree of tissue specificity.
Two injections of his antisera into guinea pigs provoked
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highly toxic effects with initial hypo- followed by hyper-
leucocytosis. He also noted that anti-bone marrow serum
was more effective than anti-mesenteric lymph node serum.
Funck (1900) raised antiserum against rabbit spleen
and bone marrow cells in guinea pigs and found that
although anti-spleen serum did not discriminate between
mononuclear and polymorphonuclear cells of rabbit peritoneal
exudate, anti-bone marrow serum destroyed polynuclear
exudate cells more readily than mononuclear cells. Similar
differences in the haemolytic activity of rabbit antisera
against guinea pig lymph node and bone marrow cells were
reported by Flexner (1902). While both anti-lymph node
and anti-bone marrow sera produced hyperplasia of the spleen
and lymph nodes In the recipient guinea pigs, only the
former produced swelling and degeneration of lymph nodes.
Bunting (1903) confirmed this finding by showing that goose
anti-rabbit lymph node serum produced an absolute lympho¬
penia which lasted at least k days after injection, and
that this was followed by marked lymphocytosis. He also
reported a transient lymphopenia in recipients of normal
goose serum, but this was not followed by lymphocytosis.
The protracted lymphocytosis was not seen in the recipients
of goose anti-bone marrow serum.
The first attempt to raise antiserum against thymus
cells was made by Moorehead (1905) though this was
unsuccessful. However, Ritchie (1908) produced duck
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anti-guinea pig thymus serum, a single injection of which
caused leucocytosis in the recipient guinea pigs.
Pappenheliner (1917) using the trypan blue dye
exclusion test as criteria for the damage to cells in
vitro, studied the effect of an anti-thymocyte serum
on cells from thymus and those from lymph glands, and
from the results shoving an equal injury to the two types
of cells, he concluded that these cells were histologically
related. He also demonstrated that the lymphotoxic and
lyraphagglutinating factors in the antisera against both
thymus and tonsillar lymphocytes were distinct from h&emo-
lytic and haemagglutinating factors since they could be
separated by specific absorption.
Antisera against polymorphonuclear neutrophils were
prepared by Ledingham and Bods011 (1915) and Chew, Stephens
and Lawrence (1936). These antisera exhibited some degree
of specificity in vitro and when injected they caused a
drop in the granulocyte but not the lymphocyte counts.
All these early efforts to raise antisora against
lymphoid cells have yielded rather weak products with poor
specificity. It was not until 1937 that Chew and Lawrence
prepared a consistently powerful anti-guinea pig lymph node
serum. Before use the antiserums was heat-inactivated to
destroy the complement, absorbed with guinea pig erythro¬
cytes to remove haemagglutinins and haemolysins, and with
sheep erythrocytes to remove Forssman antibodies. A
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single intraperitoneal injection of this serum into guinea
pigs resulted in marked lymphopenia which lasted up to 40
hours and, a repeated course prolonged the effects for up
to 10 days whereafter the lymphocyte counts returned
towards the normal. These findings were confirmed by
Cruickshank (1941). Using rabbit anti-rat lymphocyte
serum, he demonstrated that the lymphopenia produced by
this antiserum was limited to rats; it did not have the
same effect in mice or rabbits.
Since the successful demonstration during the first
half of this century of a definite role of lymphocytes in
many immunological reactions it seemed reasonable to
examine if antisera against lymphoid cells could alter the
course of such reactions. Woodruff and his colleagues
tried to influence antibody response against Salmonella
antigen by administering anti-lymphocytic serum into
previously immunized rats. Contrary to their expectations,
this treatment failed to produce any significant changes in
the antibody titres of the recipient animals (Woodruff,
Foreman and Fraser, 1951) • However, in these experiments
they showed lyraphocytotoxic activity of anti-lymphocytic
serum in both in vivo (Woodruff, Foreman and Fraser, 1951)
and in vitro systems (Woodruff and Foreman, 1951)•
Hie first experiments showing a significant suppression
of an immunological reaction by anti-lymphocytic antibody
wore reported by Inderbitzen (l95u). He showed that a
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single injection of rabbit anti-guinea pig lymphocyte
serum suppressed contact sensitivity reaction against
dinitro-chlorobenzene and tuberculin reaction in the
recipient guinea pigs. By contrast, antiserum against
neutrophils did not show any suppressive effect. His
findings were confirmed by Wilhelm and his colleagues
who suppressed contact sensitivity to dinitro-chlorobenzene
in guinea pigs with rabbit anti-guinea pig lymphocyte serum
(Vilhelin, Fisher and Cooke, 1938) and by Vaksman, Arbouys
and Arnason (1961). The latter group of workers also
found that anti-lyraphocytic serum caused a suppression of
experimental autoallergic encephalomyelitis, but it had
only a marginal effect on the reversed passive Arthus
reaction and was without effect on the passive cutaneous
anaphylaxis reaction. Woodruff and his colleagues,
continuing their initial work with antiserum against rat
thoracic duct lymphocytes, showed a significant prolongation
of skin allografts by administering the antiserum prior to
grafting (woodruff and Anderson, 1963).
In the past decade numerous groups of workers have
been investigating the effects and the mode of action of
anti-lymphocytic sera using a variety of experimental
models and an immense amount of data has accumulated showing
the effects of anti-lymphocytic serum on different aspects
of Immunological reactions. The majority of these
observations have been collectively summarized in several
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rocent reviews (James, 1967a, 1969; Medawar, 19^9; Sell,
19>9; Lance, 1970c; Taub, 1970; Jooste, 1970; Holland
and Nairn, 1972).
PRODUCTION OF ANTI-LYMPHOCYTIC SERA
Choice of animals
<
Antisera against lymphoid cells from experimental
animals and man have been prepared in a variety of animals
including rabbit, horse, sheep, cow, pig, monkey, goat,
duck and guinea pig. Although the general body of
evidence indicates that the choice of animal for the
production of the antisera mainly depends on individual
requirements and convenience, some of the observations
suggest that the properties of anti-lymphocytic sera may
be influenced by the specie® of animal they are produced
in (cited by James, 19^9, 197-b; Rolland and Nairn, 1972).
On the basis of a relatively poor immunogenicity of rabbit
globulin compared to equine globulin, the former species
is favoured by some workers for the production of both
human and murine anti-lymphocytic sera (Dresser and Gowland,
I9'jb; Araemiya, Kashiwagi, Putnam and Starzl, 1970). Some
workers also prefer the goat and the pig to the horse for
raising anti-lymphocytic serum (Sutherland, Morriss and
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Broad, 1970} Binns, Simpson, Nehlsen and Ruszkiewicz, 1970).
In contrast Southworth and her colleagues (Southworth,
Ohamian, Plate and Amos, 1970) have advocated the superiority
of the horse over the goat and cow. Indeed the choice of
animal species may also depend on the species of lymphoid
cell (antigen) donor. It has been observed that while
duck and chicken produce only weak and poor antisera
against mouse lymphoid cells, they give a satisfactory
antiserum when immunized against rabbit lymphoid cells
(Reithmftler, 19o7S Jooete, Lance, Levey, Modawar,
Ruszkiewicz, Sharman and T&ub, 19>6). In conclusion it
is not possible to lay any hard and fast rule on the most
suitable species in which to raise anti-lymphocytic serum
until the necessary information on certain relevant factors
is available. These include the responsiveness of the
antiserum producing species to vital lymphoid cell antigens,
the distribution of antibody activity in immunoglobulin
classes or subclasses and their biological functions, and
the relative immunogenicity and tolerogenicity of immuno¬
globulin classes or subclasses in the recipient species.
Choice of antigen
Anti-lymphocytic sera with variable leucocytotoxic
and immunosuppressive properties have been prepared by
using cells from lymph nodes, peripheral blood, spleen,
thoracic duct lymph and thymus. From various reports it
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appears that antiaera against thymus cells are more potent
immunosuppressants than those against other lymphoid cells.
Anti-spleen and anti-lymph node sera have been found to be
poorer in their immunosuppressive properties and worse for
their general toxicity (Nagaya and Sieker, 1965; Balner
and Dersjant, 1967; Greaves, Tursi, Playfair, Torrigiani,
Zamir, and Roltt, 19<j9; Wood and Vriesendorp, 19^91
Argyris and Plotkin, 1970; Girardet, Glass, Patti and
Gardner, 1971)•
Anti-lymphocytic serum for experimental and therapeutic
usage in man has been prepared against human thoracic duct
and peripheral blood lymphocytes (Monaco, Wood and Russell,
19671 Starzl, March!oro, Hutchison, Porter, Cerilll and
BrettSchneider, 1967; Traeger, Carraz, Fries, Perrin,
Saubier, Bernhardt, Revillard, Bennett, Archimbaud and
Brochler, 1969), infant thymic lymphocytes (Woodruff, 1967)#
and spleen cells (iwasaki, Porter, Amend, Marchioro, Zuhlke
and Starzl, 1967)• Indeed certain authors have suggested
the use of thoracic duct lymphocytes to raise antisera of
better specificity and greater potency (Pichlraayr, 1970;
Traeger, Fries, Revillard, Durix, Carraz and Plan, 1970).
In addition to intact lymphoid cells, lyophilized
thymus cells (Jankovic, Isakovic and Petrovic, 1970),
subcellular fractions of lymphocytes (Lance, Ford and
Euszkiewicz, 1966; Gozzo, Rule and Gentile, 1969;
Waraatz, Schieffarth and Baier, 1969; Zola, Mosedale and
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Thomas, 1970) and soluble extracts from mouse and human
lymphocytes (Zola, Thomas, Mosedale and Courtenay, 1971)
have been used.
Immunization schedule
In general, effective anti-lymphocyte sera are produced
by two to four injections of lymphoid cell antigens given
one or two weeks apart, subcutaneously or intravenously
(Levey and Medawar, 19o6a; Sutthiwan, Shorter, Hallenbeck
and Elveback, 1969)• The incorporation of adjuvant into
the antigen preparation can result In the production of
sera with higher antibody titres, although It is claimed
that a lot of activity against non-lymphoid antigens may
develop In the serum and consequently the product may give
rise to considerable toxic reactions in the recipient
animals (jooste, Lance, Levey, Medawar, Ruszkiewicz, Shartaan
and Taub, 19o8). In contrast, there is some suggestion
that the adjuvant-produced antisera aiay on occasions be
less toxic (Wood and Vriesendorp, 1969; Perper, Lyster,
Monovich and Dowersox, 1970; Malbfass, Paravicini, Schaffer,
Mich&alis and Staib, 1971). However, the benefits of using
adjuvants to raise ALS of greater immunosuppressive activity
have often been found doubtful (Wood and Vriesendorp, 1969;
Sterling, Elveback and Shorter, 1970).
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Active fractions
The immunosuppressive activity of ALS is associated
with the Y-globulin fraction and the activity against
lymphoid cells can be specifically absorbed by various
lymphoid cells. The distribution of antibody activity
in different immunoglobulin classes and subclasses may
depend upon many factors known to influence the immune
responses. However, the bulk of immunosuppressive
activity in ALS is generally associated with the 7S
Y-globulin fraction. This fraction is also rich in
lymphoagglutinating, lymphocytotoxic and lymphocyte-
transforming activities (James and Hedawar. 1967; Woodruff.
James, Anderson and Reid, 1967; James, 1969; All&rdyce,
Anderson, Vaerman and James, 1973)*
BIOLOGICAL PROPERTIES OF ANTI-LYMPHOCYTIC SERUM
Effect on circulating lymphocytes
A single injection of anti-lymphocyte serum causes
an acute fall in the circulating lymphocyte count (Chew
and Lawrence, 19371 Woodruff and Anderson, 1963;
Jeejeebhoy, 1965b; Gray, Monaco, Wood and Russell, 19u6)
which recovers fairly quickly, often despite the continuation
of the anti-lymphocyte serum treatment (Nagaya and Sieker,
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19651 Anderson, James and Woodruff, 1967). However,
several authors have found that lymphopenia could be
maintained for longer periods by frequent and prolonged
administration of the anti-lymphocytic serum (Monaco,
Abbott, Otherson, Simmons, Wood, Flax and Russell, 1966)
Atai and Kelly, 1967? Pichlxaayr, Ilrende 1 and Zenker, 19671
Clunie, Nolan, James, Watt and Woodruff, 1968; Denman and
Frenkel, 1968b).
No permanent effects of chronic anti-lymphocyte serum
treatment on other blood cell counts have been established.
A transient reduction in granulocyte and monocyte counts
has been reported but they return to normal more quickly
than lymphocytes (Pichlmayr, Brendel and Zenker, 19671
Ono, Bell, Kashiwagi and Sterzl, 1969)* Increased
granulocyte counts have also been reported following anti-
lymphocyte serum treatment (Sacks, Filippone and Hume, 1964}
Ono, DeWitt, Wallace and Lindsey, 1969)*
The significance of lymphopenia as an indication of
immunosuppressive potency of anti-lymphocytic serum has
been rather doubtful. Indeed correlations have been
reported firstly between the degree of lymphopenia and
graft survival by a particular anti-lymphocyte serum (Rule
and Judd, 1968f Taub, 1969) and secondly between the return
of lymphocyte counts to normal levels and the onset of graft
rejection (PichJLmayr, Brendel surd Zenker, 1967? Lawson,
Kills, Kirchheim and Hodges, 1967? Clunie, Nolan, James,
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Watt and Woodruff, 1968). However, contrasting observations
have been reported indicating a lack of correlation between
lymphopenia and immunosuppression. For example, an anti-
lymphocytic serum may produce lymphopenia but cause no
significant prolongation of graft survival (Herman and
Schloerb, 19o7)» Furthermore, a reverse relationship has
also been observed (Grogan and Hardy, 19671 Guttman,
Carpenter, Lindquist and Merrill, 19>7i Simmons, Ozerkis
and Hodm, 1968).
Histological changes
The histological changes following treatment with
anti—lymphocytic serum in the lymphoid organs are due to two
factors; the destruction or removal of certain populations
of lymphocytes, and the proliferation of other lymphocytes,
plasma cells and reticulocytes. The secondary effects
like increased phagocytosis and migration of lymphoid cells
from primary lymphoid organs to the periphery may also
contribute to the histological changes. Following anti-
lymphocytic serum treatment, a marked reduction in the
cortical region of the thymus has been noticed by several
authors (Nagaya and Sieker, 1966a; Denman and Frenkel,
1967; Bitterman and Shorter, 1968; Levey and Taub, 1969;
Simpson and Nehlsen, 1971). The thymic lymphopenia lias
been attributed by Denman and Frenkel (1968b) to the
migration of small lymphocytes into the circulation rather
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than due to a direct effect of anti-lymphocytic serum on
the thymus itself. This is consistent with the electron
microscopic observations made by Deriraan and Frenkel (1968a)
who failed to find any damaged lymphocytes within the thymus*
Animals treated with anti-lyraphocytic serum show a
marked lymphocytic depletion in the periarteriolar areas
of splenic white pulp with a reduction in the sisse and the
number of lymph follicles (Nagaya and Siokor, 1966a| Dorunan
and Frenkel, 19671 Taub and Lance* 1968| Simpson and
Nehlsen, 1971). Local areas of necrosis and signs of
local destruction of lymphocytes have been noticed by both
light (Gray, Monaco, Vood and Russell, 1966) and electron
microscopy (Deiunan and Frenkel, 1968b). Concurrent
hyperplasia of the red pulp of the spleen is also associated
with the anti-lymphocytic serum treatment but this varies
with different ant i-lymphocytic serum preparations. An
increase in reticulocytes, plasma cells and their precursors
and large pyroninophi11c cell populations has frequently
been reported (Taub and Lance, 19~»8f Barth, Hunter,
Southworth and Rabson, 19j9; Simpson and Mehlsen, 1971)*
Marked depletion of lymphocytes in the paracortical
areas of lymph nodes has been noticed following a single
dose of anti-lymphocytic serum* This is associated with
damage to and disintegration of lymphocytes in these areas
(Woodruff and Anderson, 19631 Turk and Willoughby, 19671
Bemoan and Frenkel, 19o8aj Taub, 1969). A prolonged
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course of anti-lymphocyte serum may also result in the
necrosis of these areas (Gray, Monaco, Wood and Russell,
19o6). Several investigators have noted hyperplasia of
plasma cells, reticulocytes and their precursors in th©
lymph nodes of anti-lymphocytic serum treated mice (Gray,
Monaco, Wood and Russell, 1966} Levey and Medavar, 1966aJ
Balner and Dersjant, 1967; Taub and Lance, 1968).
Hie hyperplasia, both in the spleen and the lymph nodes
has been attributed to th© immune response of the recipient
animals to constituents of the anti-lymphocytic serum since
similar although less rigorous changes occur after the
administration of normal rabbit serum (Taub and Lance,
1968| Simpson and Nehlsen, 1971)* In animals previously
made tolerant to normal serum XgG, anti-lymphocytic serum
IgG produced considerably leas hyperplasia (Taub and Lance,
1968| Rodriguex-Paradisi, Thierfelder, G$tze, Eulitz and
Beil, 1970).
In vivo localization of anti-lymphocytlc serum
There is no general agreement on the quantitative
distribution of anti-lymphocytic globulin in various lymphoid
organs. This has probably arisen from differing sensitivit¬
ies of the methods used for localising and the very 1ow
levels of th© activity being measured. There is however,
a substantial amount of evidence that anti-lymphoeytic
antibodies combine mainly with peripheral lymphocytes and
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only small amounts find access to the central lymphoid
organs (reviewed by Rolland and Nairn, 1972).
Effect on tissue grafts
The first attempts to prolong skin allografts using
anti-lymphocytic serum were made by Vaksaan and his
colleagues in guinea pigs (waksman, Arbuoys and Arnason,
1961). In these experiments they achieved only a marginal
prolongation of skin allografts. The first really
significant prolongation of skin allografts by anti-
lymphocytic serum was demonstrated by Woodruff and Anderson
(1963). Various workers have since confirmed the pro¬
longation of skin allografts in different species including
rats (Woodruff and Anderson, 196**; Nagaya and Sieker, 1965;
Jeejeebhoy, 1965a,b, 19o7)» mice (Levey and Medawar, 1966a,b;
Monaco, Wood, Gray and Russell, 1966), pigs (Lucke, Immelraan,
Syraes and Hunt, 19^8), monkeys (Balner and Dersjant, 1967)
and man (Monaco, Wood and Russell, 1967? Monaco, Wood,
van der Werf and Russell, 1967? Najarian, Simmons, Moberg,
Gewurz, Soil and Tallent, 1970).
The immunosuppressive effects of anti-lymphocytic
sera are not confined to skin allograft rejections. They
have been found effective in combating the rejection of
renal allografts in various species (Abaza, Nolan, Watt
and Woodruff, 1966; Monaco, Abbott, Otherson, Simmons,
Wood, Flax and Russell, 1966; Lawson, Ellis and Hodges,
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19o6; Huntley, Taylor, Iwasaki, Marchioro, Jaejeebhoy,
Porter and Starzl, 1966; Pichlmayr, 1967* Starzl,
Marchioro, Porter, Iwasaki and Cerrilli, 1967} Starzl,
Groth, Terasaki, Putnam, Brettschneider and Marchioro,
1968), homologous cardiac grafts in dogs (Halpern, Cachera,
Lacombe, Hathaway, Crepin, Huang, Leandri, Laurent and
Dubost, 1968), homologous liver transplants in the dog and
man (starzl, Marchioro, Faris, McCardle and Iwasaki, 1966)
and corneal allografts in rabbits (Valtoian, Faulkner and
Burde, 19o9). Anti-lymphocytic sera have been effective
in prolonging not only allogeneic tissue, but they have also
been shown to facilitate the survival of heterografts of
skin (Monaco, Wood and Russell, 19o6), human mammary tissue
(Lance and Medawar, 1968) and human neoplastic tissue
(Phillips and Gazet, 19->7) in mice and rats.
The immunosuppressive effects of anti-lymphocyte sera
on horaograft survival have been shown to be affected by the
dose of the antiserum (Levey and Medawar, 196ob; Lance,
19o8; Symes, Inmelman, Lucke and Mansell, 19^9» Najarian,
Simmons, Moberg, Gewurz, Soil and Tallent, 1970), timing
of anti-lymphocyte serum treatment in relation to the
application of graft (Monaco, Wood, Gray and Russell, 19^6;
Starzl, Marchioro, Hutchison, Porter, Cerrilli and
Brettschneider, 1967? Clunie, Nolan, James, Watt and
Woodruff, 19t>8; Grogan, Moynihan and Hardy, 19u8|
Floersheim, 1969? Van Bekkum, Heystek and Marquet, 19~>9)
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and the prior sensitization of the recipient (Levey and
Medavar, 19o6b), but not by the antigenic disparity between
the recipient and the donor strains (Levey and Medavar,
1966a), although it may be affected by interspecies
differences (Monaco, Wood and Russell, 1966).
Effect on other cell mediated immune reactions
Apart from their effect on the survival of skin and
tissue allografts, anti-lymphocytic sera have also been
shown to influence various other cell mediated immunological
phenomena. Anti-lymphocyte serum treatment of either the
donor or the recipient of semi-allogeneic spleen cells
suppresses the graft versus host disease in mice (Boak,
Pox and Wilson, 1967; Brent, Courtenay and Gowland, 1967;
Naysmith and James, 19u8; Boak, Dagher, Carson and Wilson,
1968; Mandel and Asofsky, 1968{ Floersheim and Ruskiewicz,
1969). Furthermore, anti-lymphocyte serum is capable of
abolishing delayed hypersensitivity reactions to tuberculin
in guinea pigs, mice, rats and humans (inderbitzen, 1956}
Wakstoan, Arbuoys and Arnason, 1961; Russe and Crowle,
1965; Currey and Zlff, 1967; Brunstetter and Claman, 1968),
to diphtheria toxoid in guinoa pigs (Waksman, Arbuoys and
Arnason, 1961), to bovine serum albumin in rats (Nagaya
and Sieker, 1966b), to ovalbumin in mice (Russe and Crowle,
1965) and to microbial antigens in mice and humans (Monaco,
Wood and Russell, 1967; Brunstetter and Claman, 1968;
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Domingo and. V&rren, 19o8; Adarason and Cozad, 1969)*
Contact sensitivity reactions to dinitro-chlorobenzene
have also been suppressed by anti-lymphocyte serum in
guinea pigs and chimpanzees (Xnderbitasin, 195b; Vilhelra,
Pisher and Cooke, 1958; Waksman, Arbuoys and Arnason, 1961;
Turk and Willoughby, 1967; Balner, Bysvoogel and Cleton,
1968).
These findings provide formidable evidence of an
effect of anti-lymphocyte sera on those lymphoid cells
and tissues which are associated with the development of
cell mediated immune reactions in various species. Other
suppressive effects of anti-lymphocytic sera like those in
immediate hypersensitivity (Vaksmart, Arbuoys and Arnason,
1961; Polak and Turk, 19o9)» Arthus-type reactions to
ovalbumin (Turk and Polak, 19->9) and other acute inflammatory
reactions to various agents (Waksman, Arbuoys and Arnasun,
1961; Morris, Bondoc and Burke, 1966; Turk, Willoughby
and Stevens, 1968; Perper, Glen and Monovich, 1969) may
be due to the reactivity of antisera against factors other
than lymphocytes. Some of these activities have been partly
attributed to antibodies against lymph node permeability
factor (Turk and Villoughby, 1967)» macrophage components
(Field and Hughes, 1969) or serum complement (villoughby,
Polak and Turk, 1968; Turk and Villoughby, 1969) or to
changes in local histamine concentrations (inderbitzin,
1956; Wolf-Jurgensen and Zachari&e, 1970)•
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T1IL EFFECT OF ANTI -LYMPHOCYTE SERUM ON THE HUMORAL
IMMUNE RESPONSE
Whereas there Is a general agreement over the effective¬
ness of anti-lymphocytic sera in prolonging the survival of
homologous and heterologous grafts and in suppressing various
other immunological reactions in which cell mediated immune
mechanisms are chiefly implicated, the views relating to
their effect on humoral immune reactions are far less
uniform. Although primary immune responses to a number
of antigens have been shown to be impaired in anti-lymphocyte
serum treated animals, there are certain antigens which
appear refractive to the reagent. Furthermore, rather
divergent views are held regarding the effect of anti-
lymphocyte serum on the secondary humoral immune responses
to a variety of antigens.
Certain results reported by some workers indicate a
clear dichotomy in the effectiveness of anti-lymphocytic
serum to suppress humoral and cellular immune responses.
For example, Lance and Batchelor (19jQ) showed that CBA
mice chronically treated with anti-lymphocyte serum and
grafted with A-strain skin ultimately developed circulating
antibodies directed against A-strain histocompatibility
antigens, although at this time they still allowed a complete
suppression of transplantation immunity to these antigens.
Another anomaly was observed in animals which were
-33-
trested with anti-lymphocyte serum for a significant length
of time prior to the application of allografts. These
animals developed antibodies to antilymphocytic globulin
although their response to allografts was moderately to
severely impaired (Currey and Ziff, 1966; Guttman,
Carpenter, Lindquist and Merrill, 1967* Anderson, Clark,
James, Ueid and Woodruff, 1967; Jasin, Lourie, Currey and
Ziff, 1968). These antibodies are made in increasing
amounts as anti-lymphocyte treatment is continued despite
the severe suppression of various cell mediated imrnunological
reactions. These observations on the production of antibody
to anti-lymphocyte globulin have been attributed to relatively
greater immunogenicity of anti-lymphocyte globulin in relation
to it8 normal globulin counterpart (Lance and Dresser, 1967;
Howard, Asfis and Woodruff, 19u8; Howard, Dougherty and
Mergenhagen, 19 ;8; Golub and Weigle, 19>9; Kind and Ako,
1971I Revillard and Brochler, 1971)• Contrary to these
findings, others have claimed the anti-lymphocyte serum
exerts an antidotal effect (Monaco, Wood, Gray and Russell,
1966; Xwasaki, Porter, Amend, March!oro, Zuhlke and Starzl,
1967; Rule and Judd, 1968; Levey and Medaw&r, 19^6a,b).
These discrepancies led to the belief that anti-
lymphocyte serum could suppress ceil mediated immune
responses without affecting the humoral immunity.
However, the observations made by other workers with
heterologous antigens proved contrary to this concept.
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The effects of anti-lymphocyte serum on humoral immune
responses to a variety of antigens have been studied and
the results are far from uniform.
Effect on the primary insnune response
The effect of anti-lymphocyte serum has been most
extensively studied in mice challenged with sheep erythro¬
cytes . The earlier attempts to influenee the humoral
antibody responses with anti-lymphocyte serum were rather
inconsistent. For instance, Jeojeebhoy (l9o5a) was unable
to suppress by anti-lymphocyte serum treatment the antibody
response in rats against sheep erythrocytes and tetanus
toxoid. Similarly, Monaco and his colleagues found that
anti-lymphocyte serum had very little effect on the antibody
response of mice to sheep erythrocytes (Monaco, Wood and
Russell, 19>5). Nevertheless, anti-lymphocyte serum
given to rats and mice following adult thymectomy had a
significant suppressive effect on the antibody response
to these antigens (Jeejsebhoy, 19<>5a| Monaco, Wood and
Russell, 19^5* Leuchars, Wallis and Davies, 19^8).
In contrast the later studies showed that anti-
lymphocyte serum could suppress the primary immune response
to various antigens. Monaco and his colleagues reported
a successful suppression of primary antibody response to
sheep erythrocytes in mice treated with anti-lymphocyte
iscrum (Monaco, Wood, Gray and Russell, 1906) • Similarly,
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successful suppression of ixrimary anti-sheep erythrocyte
response has been reported by several authors in both rats
and mice (James and Anderson, 19671 Prenkel, Lieberraan and
Baum, 19->7; Leuchars, Wall is and Davies, 1968; James,
Pullar and James, 1968; Riethmuller, Stein and liausen,
1968; Witz, Yagi and Pressman, 1968; Stewart and Cohen,
1969; Baum, Lieberman and Frenkel, 1969; Barth, Hunter
and Southworth, 19o9).
AfJart from sheep erythrocytes, the primary immune
responses to other antigens have been shown to be suppressed
by anti-lymphocyte serum treatment. For example, anti-
lyraphocytic serum has been shown to suppress primary immune
responses to bovine serum albumin in rats (James and Jubb,
19t»7» James, 1968, 1970) and in mice (James and Milne,
1971, 1972; Marshall and Knight, 1969; Mitchison, 1970,
1971b; Lance, 1970a,b; Nehlsen, 1971a,b) Salmonella-II
antigen (Gray, Monaco and Russell, 19->4; Lance, 1970b),
E. coli lipopolysaccharide (Allen, Friedman and Mills,
1969)» keyhole limpet haemocyanin (Nehlsen, 1971a#b), goose
erythrocytes and horse spleen ferritin (Kerbel and Eidinger,
1971) and type III pneumococcal polysaccharide (James and
Milne, 1971). In addition anti-lymphocyte serum has been
shown to suppress complement fixing antibody response to
lymphocytic choriomeningitis virus (Lundstedt and Volkart,
1967; Volkart and Lundstedt, 19j8) and neutralizing anti¬
body response against mouse pox virus (Blanden, 1970).
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Anti-lyraphocyte sera not only suppress antibody responses
to heterologous antigens* they have beon shown to exert their
immunosuppressive effects in experimental as well as spon¬
taneous autoimmune reactions. Suppression of clinical
manifestations has beon achieved in cases of adjuvant
arthritis in rat© (Currey and Ziff, 19o?» 19>8; Posganza
and Stewart, 1970), allergic encephalomyelitis in guinea
pigs (Waksxaan, arbutoys and /unason, 1961; Liebowitz,
Less of and Kennedy, 19o8} Field, 19-»9), thyroiditis in
rats (Kalden, James, Williamson and Irvine, 19^8) and
nephritis in rats (Barafoas, James {and Lannigan, 19o9),
Furthermore bemoan and his colleagues have reported an
impaired development of haeraolytic anaemia with positive
anti-globulin reaction in New Zealand Black mice treated
with anti-lymphocyte serum (jbenman, Demaan and Holborow,
19^7S Denctan, Russell, Loewi and Derunan, 1971),
beajjite the bulk of evidence on the suppressive effect
of anti-lymphocyte serum on the humoral immune response,
there are a number of reports Indicating the inability of
this reagent to suppress antibody formation against certain
antigens. Whereas Nehlsen (l971a»b) ©howed suppression
of antibody response to keyhole limpet liaemocyanin in CBA
mice, Kerbel and Eidinger (l97l) failed to achieve this
effect in Swiss mice in the earlier phase of the immune
response to this antigen. Similarly, anti-lyiaiihocyt©
antibody has often failed to suppress antibody responses
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to rat erythrocytes, polyoma virus (Nehlsen, 1971a)»
Brucella abortus (Pichlmayr, Brendel and Zenker, 19^7)
and Salmonella typhi 'H* antigen (Lance, 19o8). The
reason for this discrepancy may lie in the design of
various experimental models.
In addition several reports have indicated that the
immune responses which require little or no participation
by thymus cells are augmented by the anti-lymphocyte serum
treatment. For example anti-lymphocyte serum treatment
resulted in an enhanced 19S as well as 7S antibody response
to keyhole limpet haemocyanin in rats (Frenkel, Lieberman
and Baum, 19^7 * Baura, Lieberman and Frenkel, 19^9).
Similar findings were reported by Kerbel and Eidinger (1971)
who noted an enhancement of the antibody response to this
antigen in anti-lymphocyte serum treated mice. Furthermore,
3aker and his colleagues have observed that anti-lymphocyte
serum pretreatment caused up to 10-fold increase in the
antibody plaque forming cell response in Dalb/c mice
immunized with an optimal dose of type III pneumococcal
polysaccharide antigen (Baker, Uarth, Stashak and Amsbaugk,
1970; Baker, Stashak, Arasbaugh, Prescot and Darth, 1970;
Barth, Baker, Stashak and Amsbaugh, 1971). The latter
group of workers attributed this enhancement to the
preferential inactivation of a suppressed or •T* cell
population which controlled or inhibited antibody formation
by *6* cells.
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Lffect on the secondary jgaaune response
Reports on the efficacy of anti-lymphocyte serum to
influence secondary humoral immune responses are far more
controversial than those on the primary ones. Some
workers have reported a suppression by their antisera of
the secondary response to certain antigens while others
have shown little or no effect of anti-lymphocyte serum
on the secondary response to the same antigens. Also,
the ability of an anti-lymphocytic serum to suppress
secondary responses appears to be influenced by the antigen
under test. Furthermore, the species and the strain of
animals used in these studies seems to contribute towards
this discrepancy.
Like the studies undertaken on the effect of anti-
lymphocyte serum on the primary responses, the bulk of
studies on the secondary humoral immune responses have
also been carried out with sheep erythrocytes and bovine
serum albumin. The earlier efforts to suppress the secondary
antibody response to sheep erythrocytes proved unsuccessful
(Monaco, Wood and Russell, 19>5t Monaco, Wood, Gray and
Russell, 19bo), unless the animals were thymectomized in
adult life prior to receiving the anti-lymphocyte serum
treatment (Monaco, Wood and Russell, 19o5)« These
findings were supported by the observations of James and
Anderson (19^7) and iiauta, Lieberman and Frenkel (l9u9)»
who also failed to significantly suppress the secondary
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haemagglutinin response to sheep erythrocytes in rats.
Similarly experiments performed in rats (James and Jubb,
1967) in CDA mice (Lance, 1963a, 1970a»b) indicated
that anti-lymphocyte serum had very little immuno¬
suppressive effect on the secondary humoral immune response
to bovine serum albumin. However, there was a marginal
suppression of the secondary humoral response to Salmonella
•H* antigen in CBA mice when anti-lymphocyte serum was
administered prior to the priming of these mice (Lance,
1970a).
The most convincing evidence of the suppression of
the secondary humoral immune response was found by Barth
and Southworth (1968) who observed that anti-lymiohocytic
antibody treatment prior to either priming or the secondary
challenge dose severely impaired both IgM and IgG responses
of Balb/c mice, although the secondary agglutinin responses
in these mice remained comparable in both anti-lymphocyte
globulin treated and control animals. Similarly CDA mice
treated with four doses of anti-lymphocyte serum on
alternate days before the primary immunization, when given
a secondary challenge with sheep erythrocyte© five weeks
later, showed significantly depressed haemagglutinin titres.
Hie secondary response, just like the primary response, was
more affected by anti-lymphocyte serum in thymectomizod
mice than in sham-operated ones (Leuchars, Vallis and
Davies, 1968).
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In contrast to the aforementioned findings with bovine
serum albumin, Marshall and Knight (19>9) observed a
suppression of the secondary response to this antigen
administered in Freund*s complete adjuvant following anti-
lytaphocytic serum treatment. The suppression was directly
proportional to the priming antigen dose. The fact that
these authors measured the antibody response by passive
haemagglutination technique may be of some significance.
FACTORS INFLUENCING THE IMMUNOSUPPRESSIVE EFFECT OF
ANTI-LYMPHOCYTE SERUM
The dose of the anti-lymphocyte serum
line of the factors commonly accepted to have a bearing
on the suppression of immune responses by anti-lymphocyte
serum is the dose of the antiserum administered. This
would inevitably be related to the properties of an individual
anti-lymphocyte serum preparations its specificity and
potency. Thus graft prolongation has been shown to be
directly related to the dose of anti-lymphocyte globulin
administered (Bitterman and Shorter, 19od; Grogan, Moynihan
and Hardy, 19o8j Mandol and Asofaky, 19 >8; Symes, Inanelman,
Lucke and Mansell, 19 j9 J Najarian, Simmons, Moberg, Gewurz,
Soil and Tallent, 1970). It has also been shown that a
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large amount is more effective when given as a number of
smaller doses (Lance, 19^8; Levey and Medawar, 1966b?
Byrnes, Immelman, Lucke and Hansell, 1969? Wood and
Vriesendorp, 1969). This relationship botween the dose
of antiserum and the degree of immunosuppression has been
shown to hold true for humoral immune responses as well
(Monaco, Wood, Gray and Russell, I960? James and Milne,
1972).
Timing schedule of the anti-lymphocyte serum treatment
Although the time of anti-lymphocyte serum administration
in relation to the application of grafts is not so critical
for its prolongation (Levey and Medawar, 1966b? Greaves,
Tursi, Playfair, Torrigiani, Zamir and Roitt, 1969? Jooste,
Lance, Levey, Medawar, Ruszkievicz, Sherman and Taub, 19-8),
this is very important in the suppression of humoral immune
responses to a variety of antigens. Berenhaum (19&7)
showed that the immunosuppressive effect of the anti-
lymphocyte serum was maximum when given 3 days before
sheep erythrocytes, but it waned as the time between the
antiserum and the antigen was reduced and it completely
vanished when the antiserum was delayed up to 2-3 days
after the sensitization. In parallel studies, James
(1967b) noticed the inefficiency of anti-lymphocyte
serum to suppress the immune response of rats to bovine
serum albumin when administered after the antigen.
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These findings were confirmed by Baroni and his colleagues
who found that although anti-lymphocyte serum given up to
30 days before sheep erythrocytes effectively suppressed
the immune response, it was completely ineffective when
given two days after the antigen (Baroni, Kimball, Ward
and Wagar, 19^9)• Similar observations have been recorded
by various other workers in a variety of experimental models
(Moller and Zukoskl, 19>Sa,bj Barth, Southworth and Burger,
19 ;8j Riethmuller, Riethmuller, Stein and Hausen, 19>8;
Kayibanda and Amiel, 1970} Lance, 1970a,b). In certain
instances anti-lymphocyte serum has been shown to be
ineffective when given as early as four hours after the
antigen (Kalden, James, Williamson and Irvine, 19o9)«
The dose of immunizing antigen
—w—www—wn— 11 mm i 'Hiiw >,■—waMh*——»
The amount of antigen to which anti-lymphocyte serum
can successfully suppress the immune response seems as
important a factor as the amount of anti-lymphocyte serum
administered. Lance (1970a,b) showed that while anti-
lymphocyte serum impaired the immune response to small
doses of bovine serum albumin in mice it had little, or
no effect on the immune response to higher doses of this
antigen. Similar observations were made by Argyris and
Plotklns (1970) using sheep erythrocytes as antigen.
Furthermore, James and Milne (1972) observed that the
degree of suppression by anti-lymphocyte serum of anti-
-43-
bovine scrum albumin response in mice was inversely related
to the antigen dose administered*
Incorporation of adjuvants
Incorporation of the antigen into adjuvant has also
been shown to diminish the immunosuppressive effect of
anti-lymphocyte serum in rats (Allardyce, Hunter and James,
1970). These authors observed that anti-lymphocyte serum
suppressed the primary immune response to bovine serum
albumin administered as alum precipitate or in Freund•s
incomplete adjuvant, but did not affect the final response
to the antigen if given in Freund's complete adjuvant.
Furthermore, experiments undertaken in mice also suggest
that the ability of anti-lymphocytic serum to suppress the
response to alum-precipitated bovine serum albumin is often
curtailed by the incorporation of Bordetella pertussis into
the antigen (James and Milne, 1972).
Strain and species of animals under test
James and his colleagues showed that the ability of
anti-lymphocyte serum to suppress humoral immune response
in rats was influenced by the strain of animals under test
(James, Pullar and James, 19^9). Similar observations
were made by James and Milne (1972) in mice. Their anti-
lymphocytic serum preparation failed to suppress the primary
immune response to low doses of bovine serum albumin in
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Balb/c mice, whereas it was extremely effective in several
other strains tested. This inability to suppress these
immune responses was not related to the immune responsiveness
of the strain of animals under test or the source of lymphoid
antigen used in the production of the antiserum.
Apart from those listed above, there are several other
factors which may influence the ability of the anti-lymphocyte
serum to suppress immune responses. These factors may
include the variation in the properties of different antisera
although raised in the same manner (Jeejeeblioy and Singla,
197&)» differences in the antigen used to raise the anti-
lymphocyte serum (Argyris and Plotkin, 1970), and also
differences in the ability of the animal in which the anti¬
serum is raised to respond to the lymphoid antigens.
From the spectrum of observations listed, it is apparent
that port of the controversy relating to the ability of
anti-lymphocyte sera to suppress the humoral immune responses
has undoubtedly arisen from the fact that most of the studies
on this aspect of the immune response have been carried out
in either one strain of animals or with a single standard
dose of one particular antigen. Furthermore, in the
majority of cases, either a single preparation of anti-
lymphocytic serum has been used or the product has varied
from one experiment to the other in the same laboratory.
It was therefor# felt necessary to investigate the
effect of this rather powerful immunosuppressive agent
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(which is in some quarters still regarded as a selective
inhibitor of cell mediated immunity: Lance and Batchelorf
1968; Lance, 1970a) on the primary and secondary humoral
immune responses of a variety of strains of mice to varying
doses of different antigens. The antigens were chosen on
the basis of their thymus dependency, because it has been
suggested that anti-lymphocyte sera act discriminately
upon the cells of thymic origin (Martin and Miller, 19681
Medawar, 1969; Mitchison, 1971b).
In the bulk of the studies to be reported, a single
preparation of the anti-lymphocyte globulin was used.
However, to exclude the possibility of a single antiserum
being an atypical product, several other preparations have




Mice of the A/HeJ, C57B1, Balb/c, DBA/1, CBA arid C3H
strains were used in these studies. Generally these mice
were between two and three months old when used. The
details of the origin, H2 histocompatibility group and
the source of these mice have been listed in Table 1.
The A/HeJ, CBA and C3H mice were inbred in our own animal
house at the Department of Surgery, Edinburgh University.
The Balb/c and DBA/1 mice were kindly provided by
Dr. J.G. Howard of the Wellcome Research Laboratories,
Beckenham, Kent. These had been inbred in their animal
house at Beckenham from the original breeding pairs
obtained from the source listed in Table 1. The C57B1
mice were purchased from the Animal Suppliers Limited,
Colindale, London N.W.ll. The origin of their breeding
pairs has also been indicated in Table 1. Throughout
these studies only male mice were used.
Experimental mice were housed in plastic boxes with
five to six mice in each box. The temperature of the
mouse room was maintained at 22°C and a constant air
exchange rate to provide adequate ventilation was always
ensured. The mouse boxes were lined with wood shavings.
Mice were fed on a commercial mouse cake diet (McGregors






























































The anti-lymphocyte sera used in these studies were
all raised in horses against mouse thymocytes. The
batches la, lb, lc, and Id were obtained from a single
horse at various stages of Immunization, with a pool of
dispersed thymus cells from A/HeJ, CBA, C3H, and C57B1
mice. The anti-lymphocyte globulin preparations 2, 3,
and 4 were obtained from antieera raised in different
horses against mouse thymus cells. These were generously
provided by the Vellcome Research Laboratories, I3eckenhat»,
Kent. Details of the immunization schedules employed
in raising the different anti-lymphocyte sera have been
listed in Table 2•
Preparation of from normal and anti-lymphocyte sera
The serum was inactivated by incubating it at 5o°C
for 30 minutes after which the pH of the serum was
adjusted to b.O by the addition of N/1 sodium hydroxide.
An equal volume of 2b per cent sodium sulphate (w/v) was
then slowly added to the serum with continuous stirring;
tne final salt concentration reached was 14 per cent.
The globulin precipitate was then recovered by centrifugation
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TABLS 2 - A SUMMARY OF THE IMMUNIZATION SCHEDULES USED IN




















la 12.5 x 109 SC in FCA 0 21 1 6
lb 8.9 x 109 IV 28 38 2 11
lc 8.6 x 109 IV 99 108 3 14
Id 9.7 x 109 IV 148 164 4 11
100 x 109 IV 0,14,37.55
and 76
2
9 x 109 IV 136 10
1 X 108 SC in FCA 357 and 820 835 8
0.5 to 6xl09 SC in FCA 0,4,7.12 and
14
3
22 x 10° SC in FCA 19,21,28,32,
44 and 49
8
32 x 109 SC in FCA 59 and u3
32 x 109 IV 56,66 and 77 80 lo
1 X 108 SC in FCA 0 and 91
4





1 X io8 IV 294,301,308
and 315
332 8 8
(a) Antisera 2-4 were kindly provided by Dr. A. Phillips of the
Uellcome Research Laboratories, Beckenham, England.
(b) The lymphocytotoxic titre recorded is that noted with a lg
per cent IgG solution prepared from a bleed obtained on the
day indicated.
NOTE: Preparations Id, 2, 3 and 4 significantly prolonged A strain
skin grafts on CBA mice.
Preparations la, lb and 1c were not tested.
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and dissolved in hair a volume of 0.01M phosphate buffer
(pH 8.0; see Appendix X). The material vas re-
precipitated by adding an equal volume of 28 per cent
aodium sulphate. The final precipitate was spun down
and redisaolved in and dialyxed against 0.01H phosphate
buffer (pH 7»5l see Appendix X).
Diethyl-amino-ethyl (ddAd) cellulose (Whatman DE.ll;
exchange capacity 1.0 milli-equivalent per g.» obtained
from V. & R. Daleton, Maidstone, Kent) was washed
extensively with 0.01M phosphate buffer(pH 7*5) and
resuspended in the same buffer. During the process of
washing the fines were removed by decantation. The
exchanger was then filtered through a coarse glass sinter,
rosuspended in the equilibrating buffer and the pH adjusted
to 7*5* if necessary, by slow addition of N/l hydrochloric
acid or H/l sodium hydroxide.
The equilibrated exchanger vas added to the gamma
globulin solution (obtained by sodium sulphate precipitation)
and stirred for ten minutes to ansure adequate mixing.
Approximately one gram dry weight (equivalent of 4-5 g.
wot weight) of the exchanger was used for each initial
o
ml. of serum. After standing at 4 C for 30 minutes with
occasional stirring, the slurry was filtered through a
coarse sintered glass funnel. Entrapped IgG was displaced
from the filtered exchanger by the addition of equilibrating
buffer and further filtration. The filtrate was concentrated
-h9-
by lyophiligation and redissolving in normal Saldino.
In order to remove antibodies to mouse erythrocyte
and other histocompatibility antigens the anti-lyraphocytic
globulin vas absorbed with mouse erythrocytes • This was
achieved by the following procedure. Mouse erythrocytes
separated from freshly acquired citrated blood were washed
four times with phosphate buffered saline (FBS| see Appendix 1).
For every five volumes of IgG (2 g. per cent) preparation,
one volume of packed mouse erythrocytes were used. Mouse
erythrocytes were suspended in the IgG preparation and
incubated at 37°C for one hour. The suspension was
centrifugod and the IgG solution was recovered. The
process was repeated (usually k-5 times) until the anti-
mouse erythrocyte activity was satisfactorily absorbed.
The protein concentration of the IgG preparation was
calculated from the ultraviolet absorption at 280rap using
the following formula and adjusted to 2 gram protein per
100 ml.
U.V. absorption (at 280mp) x dilution of
Protein eoncn. the sample
(g. per cent) * ■■■«■■■ -- ■ ■"■■■■■
Extinction coefficient (i.e. 13.SO)
The standardized XgG preparation was sterilized by ultra¬
filtration through a 0.22 {A mi111pore membrane and ampouled
in small aliquot# • The sterility of the products were
routinely assessed by the Bacteriology Department, Royal




The outi-lymphocytic globulin (aLG») to be tested was
adjusted to a concentration of 1.0 g. per cent protein in
Hank's balanced salt solution (BSS). Serial dilutions
of tii© preparation were toad© in Hank's BSS (see Appendix 1)
to obtain 12->14 tubes of doubling dilutions. To each,
tube was added 0.2 ml. of dispersed and prawashed (in Hank's
BSS) thymocyte suspension containing 10' cells per ml.
Finally 0.1 ml. of fresh guinea pig complement diluted 1/10
was added to each tube. The tubes were shaken to mix the
cells and incubated at 37°C in a water bath for li hours.
Prior to incubation all the reagents and the cell suspension
wore kept at 4°C. After the incubation. 1.6 ml. of trypan
blue solution (see Appendix 1) was added to each tube.
The tubes were shaken and left at room temperature for
2-3 minutes following which 0.1 ml. of 40 per cent
formaldehyde solution was added to all the tubes. The
percentage of colls killed by the ALG preparation was
estimated either on the same day or the following morning.
The cells which had been able to exclude trypan blue were
considered live. The dilution at which 30 per cent of
cells were killed was taken as the cytotoxicity tit.re for
the AlG preparations.
With each test for cytotoxicity, control tubes lacking
■31-
corapleraent or AIG or both were included. Tho result a of
tho cytotoxicity tests on various AlG preparations used in
this study ixave been summarized in Table 2.
ANTIGENS
Sheep erythrocytes (SRBC)
mm — I inJi I — m m .■ m min*i
A mixture of sheep blood with an equal volume of
Alsever*s solution was acquired from Wellcome Reagents
limited, Beckenham, Kent. Prior to administration into
mice, or use as an indicator for the assay of the immune
responses, the erythrocytes were washed four times with
phosphate buffered saline (PBS).
Purified pneumococcal polysaccharide (type III)
The preparation of the pneumococcal polysaccharide
(SSS-III) used as a thymus independent antigen in these
studies was kindly provided by Dr. James Howard (Department
of Experimental Immunobiology, Wellcome Research Laboratories
Beckenham, Kent) and Dr. J.11. Humphrey (National Institute
for Medical Research, Mill Hill, London N.W.7)* The
detailed method for the preparation of this antigen has
been reported elsewhere (Heldelberger, M&cleod, Markovits
and Roe, 1950). The product was obtained in a freeze-dried
4-, "
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state and prior to use the antigen was resolublized in
normal physiological saline to give the required concentration
of the antigen.
Bovine serum albumin (BSA)
A three time crystallized preparation of bovine ..©rum
albumin containing 10 mg. protein nitrogen per ml. (i.e.
o3 Hg. total protein per ml.) was obtained from the Armour
lharraaceutical Company, Chicago, Illinois, U.S.A. Prior
to administration into mice the antigen was adsorbed onto
•Alhydrogol* (1.3 per cent AlgO^) supplied by Danok Svovlsyr,
Copenhagen, Denmark. To achieve the adsorption, 1.6 ml. of
the standard BSA solution (lOO mg. protein) was added to
10 ml. of well suspended Alhydrogel and mixed adequately.
The mixture was incubated at 37°C for half an hour.
Following this the mixture was spun at top speed in an
MSE-Winor bench centrifuge for 20 minutes and the protein-
free supernatant was discarded. The pellet was resuspended
in an appropriate volume of sterile physiological saline
to give the required concentration of the protein per ml.
INJECTION OF ANIMALS
Normal horse IgG(NHIgG) or AJUG were injected intra-
peritone&lly as a sterile solution containing 5*0 mg. IgG
protein in 0.2—0.3 ml. volume. Unless otherwise mentioned
53-
ALG Id was used in all the experiments. In selected
experiments other ALG preparations were used.
The appropriate dose of SRBC was administered intra-
peritoneally in 0.4 ml. PBS.
The required dose of purified SSS-IXI was injected
intravenously in 0.2 ml. saline via the tail vein. To
facilitate intravenous administration the mice to be
injected were incubated at 40°C for about 10 minutes prior
to the injection.
Alion precipitated BSA was injected intraperitoneally
as Alhydrogel adsorbed suspension in 0.2 ml. sterile physio¬
logical saline.
ANTI -IMMUNOGLOBULXN SERA
Anti-mouse whole framna globulin serum
9
Mice were immunized with 10 rabbit erythrocytes
previously wasl id with PBS. Two weeks later the alee were
bled and the serum was inactivated by heating at 5o°C for
30 minutes. 0.5 ml. washed and packed rabbit erythrocytes
were suspended in 2 ml. of this mouse anti-rabbit serum
and incubated at 37°C for half an hour. The rabbit
erythrocytes thus coated with mouse gauana globulin were
washed six times with PUS. emulsified in Freund's complete
adjuvant and injected intramuscularly into the hind leg of
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the rabbit from which the erythrocytes were initially
obtained. Three weeks later the rabbit was boosted with
similarly sensitized autologous erythrocytes by intx'avenous
injection. The antiserum obtained a week later was
Inactivated by heating at 5o°C for 30 minutes, and stox'ed
at -20°C. Prior to use as a developing servan for indirect
anti-sheep erythrocyte plaques the antiserum was absorbed
with sheep erythrocytes and titrated for optimum dilution
for developing the indirect plaques. The procedures for
determining the optimum dilution of the antiserum in the
plaque forming cell assay will be described later.
Antlsera against individual mouse immunoglobulins
The antisera against different XgG subclasses (igti^,
1*2*. IgG2b^ wor® kindly provided by Professor
Stewart Sell (Department of Pathology, University of
California Medical School, San Diego, California, U.S.A.).
These antisera were raised in rabbits, and the details
of the antigens used to immunize the rabbits have been
listod in Table 3* The details of preparation of antigens
and the schedule of immunization have been documented
elsewhere (sell, Park and Nordin, 1970). These antisera
were used for detecting the cells producing anti-sheep
erythrocyte Ixaemolysins of the respective immunoglobulin
classes and subclasses. Before use each antiserum was
titrated for its optimal developing titre.
-5Ua-
TADLS 3 - IMMUNOGBNS USED FOR THIS PRE PARATIOK OF











(a) See Sell, Park and Nor*din (1970) for details.
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ASSAY PROCEDURE FOR THE DftlPNK RESPONSES
The experimental animals vere anaesthetized In ether*
The maximum possible amount of blood was drawn from the
Inferior vena cava. The intact spleens were carefully
excised from mice which had been immunized with sheep
erythrocyte or type XXI pneumococcal polysaccharide.
These spleens were immediately used for the plaque forming
cell assay, whereas the sera separated from the blood wore
stored at -20°C until they were assayed for circulating:
antibody titres against the respective antigens. In
certain experiments circulating antibody titres in
individual mice were determined at periodic Intervals
following antigenic challenge. On these occasions 0.3
to 0.2* ml. of blood was drawn from the retro-orbital sinus
at intervals. The serum was separated on the same day
and stored at -20°C prior to assay.
Anti-sheep erythrocyte response
The antibody plaque forming cell (PFC) assay was mainly
used to assess the anti-sheep erythrocyte responses.
Apart from this* the sera from all the animals challenged
with this antigen were also tested for anti-sheep erythrocyte
haemagglutinating and haemolytic antibody titres. liaoaiolyein
and haenagglutinin assays wore performed on native as well
as 2-iaercaptoethanol-treated serum • Both PPG and scrum
antibody assays were carried out on individual mice.
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Plague forming cell assay
The spleen Irani the mice to be tested was removed
and gently disrupted by means of a glass homogenizer In
wuglo's medium (Welicotae Reagents Limited) containing
100 tag. BSA per lOO ml. The dispersed cells were counted
to determine the total number of nucleated cells per spleen.
The cells were veil suspended and left to settle for
5 minutes. An aliquot of the suspension was taken from
the top of the tube and made up to 6 ml. with the BSA—
supplemented Logic's medium. The cells were suspended
by gontly shaking, and spun at 75$ r.p.ra. (l5Qg) i» an
MSB Mistral-6 centrifuge for j-7 minutes. The supernatant
was discarded and the cells were rcsuspended in an approp¬
riate volume of the medium (usually 2 ml.). The suspension
was allowed to stand for another 5 minutes and the upper
layer of the suspension containing singly dispersed cells was
carefully removed. The cell count of this suspension was
determined and if necessary it was adjusted to the required
concentration. The concentration of cells in the suspension
varied from experiment to experiment and also from group to
group in the same experiment depending upon the anticipated
plaque forming cell response of the animals under test.
This was mainly governed by the strain of animals, the
antigen dose and the treatment the animals had received
(e.g. NlilgG-treated animals were anticipated to give far
bigger response than ALG-treated ones). The PFC assay
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on test (treated with ALG) and the control (treated with
NHIgG) animals were invariably performed at the same time.
Throughout these operations the cells were kept at k°C.
The number of antibody PFC were determined by a
modification of the Jerne plaque technique (jerne, Nordin
and Henry, 1963). A stock solution of 1.8 per cent (w/v)
Agarose A-37 InduboisR (L'Industrie Biologique Francais,
Germevilliers, France) in distilled water was melted by
heating at 100°C in a boiling water bath. This was then
cooled down to 48°C and mixed with an equal volume of
double strength prewarmed (48°C) Eagle's medium supplemented
with 200 mg. Q5A per 100 ml. The mixture which was main¬
tained at U8°C in a water bath was then filtered through
glass wool which was soaked immediately before use with
warm (J»8°C) Eagle's medium. The filtered agarose was
collected in a prewarmed container. The mixture was
dispensed in one ml. aliquots in prewarmed Kahn tubes using
a prewarmed 5 ml. pipette. To this was added 0.1 ml. of
lOper cent (v/v) prewashed sheep erythrocyte suspension
in Hank's balanced salt solution and 0.1 ml. of spleen
cell suspension from the animals to be tested. The
number of spleen cells per plate were chosen such that
not more than 200 plaques were produced per plate. The
cells were mixed by gently stirring the suspension with a
wooden applicator kept in Eagle's medium at i*8°C. They
were then poured into a 5 cm. diameter disposable plastic
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Petri dish (sterilin Limited, Richmond, Surrey) laid on a
level surface. The mixture was quickly spread over the
whole area of the plate and left to set. Tests on each
spleen were performed in duplicate. The plates were
placed in a chromatography tank filled with 5 cent
COg in air and incubated at 37°C for two hours. Following
this, 2 ml. of a 1/40 dilution of preserved guinea pig
complement (wellcoaso Reagents Limited) in Hank'& BSS was
poured gently over the gel and the plates incubated for
another hour at 37°C. The complement was then poured
off and the plates were either stored at 4°C in which
case the haemolytic plaques were read the following morning
or they were covered with 1 ml. of 0.25 P©r cent (v/v)
glutaraldehyde, stored at 4°C and read within 2-3 days.
To facilitate the counting of the plaques, the plates
were placed on a grid and a hand lens was used to magnify
the plaque s.
Since the direct plaques only represented the IgM
producing cells, the cells producing other antibody classes,
were detected by the use of a developing technique described
by Dresser and Wortis (19o7). This involved the addition
of a suitable dilution of a multivalent or a monovalent
rabbit anti-mouse immunoglobulin serum with the complement.
As most antiglobulin sera inhibit IgM producing plaques
to some degree, it was necessary to determine the corrected
numbers of the developed plaques using the developing and
-59-
the inhibiting constants for the antiglobulin sera at the
dilution used. These were determined as follows.
Titration of the developing antisera
A/HeJ mice were injected intraperituneally with a low
dose (3 x 1G?) of sheep erythrocytes. Two days following
this they were sacrificed and the spleens were assayed
for direct plaque forming cells as well as the indirect
plaque forming cells, the latter being developed with
various dilutions of the anti-immunoglobulin serum to be
titrated. Since the antibody response against this dose
of sheep erythrocytes at this time after immunization is
mainly IgM, any decrease in the plaque forming cells
obtained within a constant number of spleen cells by the
incorporation of the anti-iianunoglobulin serum would
represent the net inhibition of the IgM plaques by the
antiserum dilution. Thus the inhibition constants (hi)
for various dilutions of the antiserum were calculated
by the following formulat
developed plaques (at this dilution)
(at the dilution) « - ■■ -
undeveloped (direct) plaques
Calculation of the developing constant and the optimum
9
dilution of the antiserum: Mice were immunized with 3 x 10
sheep erythrocytes and sacrificed for the PFC assay ten days
7
later. Alternatively mice were primed with 3 x 10 and
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a fortnight later they were challenged with 3 x 10 sheep
erythrocytes. The spleen cells from the latter group
were tested for PFC k days after the secondary challenge.
In both these cases in addition to a small IgM response
the mice gave considerable IgG and XgA response (Wortis,
Dresser and Anderson, 1969? Sell, Park and Nordin, 1970).
The spleens of the above mice were assayed for direct PPC
using no developing serum and indirect PFC using different
dilutions of the anti-immunoglobulin serum to be tested.
From this the optimum dilution of the antiserum to be used
for developing the indirect PFC was determined. In addition
the developing constants (KD) for the respective anti¬
immunoglobulin at its optimum dilution of use were calculated
by the following formula:
Max. dev. plaques - undev. plaques
,:n x K1 (at this dilution)
^(opt. dil.) »
Dev. plaques (at opt. dil.) - undev. plaques
x KI (at opt. dil.)
Using the inhibition and the developing constant
values the corrected indirect plaques were determined by
the following formula:
Corrected PFC « KX>(dev. plaques - undev. plaques x Kl)
(both KD and KI values were those for the optimum
dilution of the developing serum used)
The results of the titration of various anti-immunoglobulin









































































































































































































































used, and the Inhibition and developing constants for these
antisera have been recorded in Table b.
Haemagglutinatiqn teat t Doubling dilutions of the
sera under test were made in PBS In V-shaped microtitre
plates (sterilin) using microtitre dispensing pipettes
and loops (Cooke Engineering Company, Alexandria, Virginia,
U.S.A.), An equal volume (0.025 ml.) of 2 per cent (v/v)
sheep erythrocyte suspension in PBS was added and mixed.
The plates were covered with sellotape, in order to avoid
evaporation, and incubated at 37°C for one hour. At the
end of the incubation the plates were carefully shaken to
resuspend the cells and stored at b°C overnight. The
agglutinin titres were read macroscopically on the following
morning. A button of packed cells half the sisse of the
control (the well containing saline and sheep erythrocytes)
was taken as the end-point.
Ifaemolysin assayi The sera were serially diluted
(2-fold) in veronal buffered saline (VBSJ see Appendix l)
in U-shaped microtitre plates (sterilin) using the 0.025 ml.
microtitre dispensing pipette and loops. An equal volume
of 2 per cent (v/v) sheep erythrocyte suspension in VBS
was added and mixed. The plates were incubated at 37°C
for 30 minutes, following which the cells were resuspended
and 0.025 ml. preserved guinea pig complement (Wellcome)
at a 1/15 dilution was added. The plates were reincubated
—ola—
TABLE 4 - INHIBITION (Kl) AND DEVELOPING (KD) CONSTANTS FOR






imraunoglobulln 1/400 0.85 1.40
anti-Y^ 1/100 1.0 1.55
ant±-Y2a 1/100 0.72 1.0
anti-Y2b 1/100 0.40 1.51
antl-YA 1/100 0.79 1.24
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at 37°C for another hour. The plates were shaken at the
beginning, in the middle and at the end of the incubation
to resuspend the cells. The plates were stored at 4aC
overnight and the 50 per cent haemolytic titres were read
on the following morning.
2-Mercaptoethanol treatment I Whenever the determination
of 7S anti-sheep erythrocyte haemagglutinin or haemolysin
titres were desired, the sera were mixed with an equal
volume (0.025 ml.) of 0.2M 2-mereaptoethano1 in PBS in
microtitre plates and left overnight at 4°C. The treated
sera were then diluted 2-fold and tested for agglutinin
and haemolysin titres as described above.
•
Anti-pneumococcal polysaccharide response
Anti-SSS-III response was measured by assaying the
splenic plaque forming cells. In addition, sera from
these mice were tested for haemagglutinating antibodies.
In the PFC assay, sheep erythrocytes coated with pneumo¬
coccal polysaccharide (a crude preparation) were used as
indicator cells, while in the haemagglutination assays the
polysaccharide antigen was attached to mouse erythrocytes.
Preparation of crude pneumococcus polysaccharide
filtrate t The crude type III pneumococcus polysaccharide
filtrate used to sensitive sheep or mouse erythrocytes was
prepared by a method based on that described by Askonas.
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Farthing and Humphrey (i960). Freeze-dried culture of
Diplococcus pneumoniae type III was obtained from the
National Collection of Typed Culture (NCTC), Central Public
Laboratory, Colindale, London* The contents of the vial
were suspended in 5 ml. of brain-heart infusion broth
(Difco Laboratories, Detroit 1, Michigan, U.S.A.) and
incubated at 37°C overnight• Hie organisms were subcultured
on a blood agar plate and incubated at 37°C for another 16-18
hours. At this stage the purity of the culture was checked
by using Optochin (ethyl hydrocuprein-HCL) sensitivity discs
(Mast Laboratories). Individual pneumococcus colonies
were picked up from the blood agar plate and inoculated
into 10 ml. of brain-heart infusion broth. After 24 hours
of incubation the brain-heart infusion broth was added to
IOO ml. of the protein-free broth (see Appendix I) described
oy 0*Meara and Brown (1936) and incubated at 37°C for 36 to
kO hours.
Formaldehyde (final concentration 1.6 per cent v/v)
was then added to the cultures grown in the protein-froe
broth and the mixture was left at 4°C for 48 hours. The
organisms were removed by centrifugation at 6000 r.p.m.
(3000g) in an MSB *high speed 18* centrifuge. The super¬
natant fluid was recovered and dialysed against a total
of 40 volumes of PBS at k°C with at least four changes of
the buffer. The filtrate was titrated for its optimum
sensitizing ability in both PFC and haemagglutination
—oU —
assays and stored in 5 aliquots at -20°C until required.
The results of the titrations are shovn in Figures 6-7•
Sensitization of sheep erythrocytes» Sheep erythrocytes
(obtained from Wellcome Reagents) were washed four times
with PBS and made up to a 10 per cent (v/v) suspension.
An optimal volume of the crude filtrate was made up to
9 ml. in PBS and to this 1 ml. of 10 per cent sheep erythro¬
cyte buspension was added and quickly mixed. The mixture
was incubated at 37°C for one hour with frequent mixing.
The sensitized cells were washed four times with PBS and
rosuspended in Hank's BSS at a 10 per cent (v/v) concentration.
Plague forming cell aaaayi The plaque forming cells
were assayed using sheep erythrocytes sensitized with poly¬
saccharide as described above. The method adopted for the
detection of the anti-SSS-IXl PFC was essentially the same
as that described for the detection of anti-sheep erythrocyte
PFC except that in this assay preserved guinea pig complement
was replaced by fresh guinea pig serum. The spleens from
individual animals were assayed in duplicate for plaque
forming cells against both sensitized and un.sensitised
sheep erythrocytes. The specific anti—SSS-III PFC response
in each spleen was calculated by deducting the plaques
obtained with unsensitized sheep erythrocytes from those
obtained with sensitized erythrocytes. The specificity
of the assay was ascertained by the inhibition of the
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TITRATION OF PNEUMOCOCCAL FILTRATE TO SENSITIZE
SHEEP ERYTHROCYTES (SRBC) FOR PFC ASSAY
500-1
1 1 1 1 I I
0 0-2 0-4 0-6 0-8 10 1-2
VOLUME OF FILTRATE IN 10ml OF 1% SRBC SUSPENSION
FIGURE 6
-64b-
TITRATION OF PNEUMOCOCCAL FILTRATE TO SENSITIZE
MOUSE ERYTHROCYTES (MRBC)FOR HAEMAGGLUTINATION
ASSAY
1 1 1 1—I 1 1
005 0-1 0-2 03 0-4 0-8 1-6ml
VOLUME OF FILTRATE IN 10ml OF 1% MRBC SUSPENSION
FIGURE 7
-o5
ailti-pueuraococcus polysaccharide plaques L>y tlie incorporation
of purified type III pneumococcal polysaccharide* The
results of this inhibition have been shown in Figure o.
Ilaemagglutination assay» House erythrocytes were
obtained from freshly collected mouse blood* The cells
were washed four times with PBS and made up to a 10 per
cent (v/v) suspension. One ml* of this suspension was
added to an optimum quantity of crude pneumocooeus culture
filtrate in 9 of PBS* The suspension was incubated
at 37°C for one hour with intermittent shaking. Finally
the cells were washed four times with PBS and suspended at
a concentration of 0*5 per cent in PBS containing 50 Big.
I3SA per 10O ml*
Serial doubling dilutions of the serum under test
were made in 0.025 il« PBS-BSA in V-shaped microtitre trays.
An equal volume of 0*5 per cent (v/v) sensitized mouse
erythrocytes was then added to each well and the plates
were left at room temperature for two hours* They were
then reed macroscopically after tilting the plates* A
tight button from which the cells did not slide down on
tilting was considered a positive agglutination. For
each group of sera only isologous mouse erythrocytes were
used and the specificity of the test was ascertained by
the inclusion of a standard rabbit anti-SSS-III serum
(Difco) and a normal mouse serum with each test*
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FIGURE 8
SPECIFIC INHIBITION OF ANTI - PNEUMOCOCCAL POLYSACCHARIDE ( SSS-UI)
PLAQUES BY PURIFIED SSS - JH PREPARATION
AMOUNT OF SOLUBLE SSS - HI ADDED TO EACH PLATE
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Cell reconatitution of ALG—treated mice: The suspension
of spleen and thymus cells used in these studies were prepared
as described earlier. The bone marrow cells were obtained
by infusing the femur with Eagle * e medium and resuspend! ;zg
%
the cells by passing through a 21 gauge hypodermic needle.
Hie required number of cells were slowly injected into the
tail vein in a volume of 0.25 ml.
/oati-bovine serum albumin response
The antibodies to BSA were measured in individual sera
by the amaonium sulphate method of F&rr (1956) using the
modifications described by Plnekard* Weir and HeBride (1967).
This briefly Involved the following procedure.
The sera to be tested were diluted 1/10 in borate
fc offer (see Appendix l) containing 1 per cent normal mouse
serum. Prota this four or five doubling dilutions were
prepared in the same buffer. The dilutions of the test
serum were selected on the basis of anticipated magnitude
of then immune response and an end-point was always ensured,
half a ml. of each dilution of the test serum was tzansferred
into kahn tubes (75 * 12 mm. rimless glass test tubes).
Together with test serum 3 sets of quadruplicate controls
were also set up* 2 sets containing 0.5 ml. of a 1/10
dilution of normal mouse serum while the 3rd set contained
the diluent only. To all the test and control tubes was
added 0.5 til. of the radio-iodinated BSA containing
o7
0,0k or Q,k\ig. protein nitrogen per ml. The tubes were
incubated at 4°G overnight. The following morning all
the tubes (except four of the controls containing normal
serum) received 1 ml. of saturated ammonium sulphated
solution. To the remaining four of the control tubes
vna added 1 ml. 20 per cent (w/v) trichloro-acotic acid
(TCA). Immediately following the contents of the tubes
were thoroughly mixed. The tubes were incubated at k°C
for 30 minutes and then spun at 2250g for 30 minutes in
an MSE-Major centrifuge. The supernatants were discarded
and the precipitates were rcsuspended in 3 ml. of saturated
ammonium sulphate, or 20 per cent TCA as appropriate.
The tubes were again incubated at *t°C for half an hour
before recentrifugation. The precipitates were counted
in a scintillation spectrometer (Nuclear Enterprise Mk II
gamma-matic).
The two antigen concentrations, i.e. O.OJ^ and O.^mg.
protein nitrogen per ml. were used in order to determine
the relative binding affinity of the antibody in the anti-
sera.
The actual 33 per cent antigen binding capacities (ABC)
were determined by computer analysis and the results are
expressed as fig. of BSA nitrogen bound by on© ml. of
undiluted serum. The computer programme was kindly
provided by Dr. W.M. McBride (Department of Bacteriology,
Edinburgh TTriiversity) and the analyses were carried out
by the Edinburgh Regional Computer Centre.
^^Iodine labelling of BSAi Five tag. of BSA (Armour)
in 0.5 ml. PBS vas added to 0.5 ml. PBS la a small beaker
containing 2~4ftci of carrier-free 12^Iodine (Radiochemical
Centre, Amersham, Bucks. England). The mixture was stirred
with the aid of a magnetic device and while mixing 0.2 ml.
of stock solution containing 0.05 per cent (w/v) chloramine -T
(BOH. Poole, Dorset, England) in distilled water was added.
The mixture was allowed to stand for five minutes before
3 ml. of borate buffer was added. After this the contents
were carefully transferred into a dialysis tubing and
dialysed overnight against a litre of borate buffer contain¬
ing 10 per cent (w/v) potassium iodide. This was followed
by a fdrther dialysis for 72 hours against iodide-free
borate buffer with 3-J* changes of the buffer. The protein
content of the iodinated BSA preparation was determined by
the raicx-o-Kjelclah1 procedure (Kabat and Mayer, 19b1)•
Aliquots of the preparation were stored at -20°C and just
before us© they were diluted to the required protein
concentration with borate buffer containing 1 per cent (v/v)
normal mouse serum.
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PRESENTATION OF RESULTS AND STATISTICAL ANALYSIS
Anti-sheep erythrocyte response
The arithmetic mean of the plaques cm the two duplicate
plates was obtained and the PFC content in the spleen of
individual mice was calculated. Also the number of PFC
per 10 nucleated cells from individual spleens were
calculated. Fran the developed plaques per spleen the
number of corrected indirect plaques per spleen and those
per 10 nucleated spleen cells were determined. A geometric
mean of the number of plaques per spleen or plaques per 10J
nucleated spleen cells was obtained for each experimental
group. The results from each group have been expressed
as the mean PFC with the limits of one standard error from
the mean.
The arithmetic mean of both total and reduced reciprocal
lo&2 haemagglutinin and haemolysin titres were calculated
for each experimental group. The results for each group
Have been express a. tho mean log2 tltro with the limit,
of one standard error from the mean.
Anti-SSS-III response
The average number of plaques In two duplicate plates
with unsensitized erythrocytes was deducted from the average
number of plaques obtained from the two plates containing
-70-
sensitlxod cells. Thus the number of specific plaques
per spleen and per 10u nucleated spleen cells was calculated
for each Individual mouse. A geometric mean of the specific
plaques per spleen and per 10' nucleated cells was determined
for each experimental group. The results have been ex¬
pressed as the mean PFC with the limits of one standard
error from the mean.
The agglutination results for each group have been
eapreeeed a. the arithmetic mean of the iogj, titre. with
the limits of one standard error from the mean.
Anti-BSA response
The anti-BSA responses have been expressed as the
geometric mean values of antigen binding capacities of
each mouse serum together with the limits of one standard
error from the geometric mean. The relative binding
affinities for individual sera were calculated using the
following formula and have been expressed as the arithmetic
mean with the limits of one standard error from the mean.
Relative biadin* . ABC with O.OZhg. protein N ^ ^
affinity ABC with 0.2|ig. protein N
Statistical analysis
Various experimental groups were compared by means of
the two tail student's ntN test formula and the significance
of the difference between any two groups has been expressed
71
as the "pn value. All the "p" values higher than 0.05




IMMUNE RESPONSE TQ SHEEP BRTfiiROCYTBS
Effect of ALG on the primary immune response in various
mouse strains
Groups containing between 3 and 6 mice received 5 *»g.
MIIgG or AJLG(ld) intraporiton©ally on days -h and -2 and
8
were challenged with 3 x 10 SRBC by intraperitoneal
injection on day 0. The direct PFC response of the spleen
and serum antibody titres were measured five days after
the challenge* The results of these experiments have
been summarized in Table 5*
It is quite obvious from the data that this ALG
preparation has successfully suppressed the primary immune
response to this dose of SRBC in all mouse strains tested.
The magnitude of the response does not seem to determine
the degree of suppression by the ALG treatment. For
example, in A/HeJ mice, although the magnitude of the
response is greater than any other strain to this dose of
SXIBC, the degree of suppression by ALG treatment is as good
or even better than other strains which did not respond so
well (e.g. C57B1). In all instances the differences
between the NHIgG- and ALG-treated groups were highly
significant•
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TABLE 5 - THE EFFECT OF ALG ON THE PRIMARY IMMUNE































































(a) 5*0 mg. NHIgG or ALG injected i.p. on days -4 and
-2| 3 x 10® SRBC given i.p. on day O and tested
on day 5*
(b) Geometric mean with the limits of one standard error.
(c) Comparison between NHIgG and ALG groups.
(d) Number of mice in each group.
(e) Observations from two different experiments.
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In another set of experiments groups of mice vera
treated with NIUgG or ALG and challenged with SRBC as
above. Four days after the antigenic challenge, the
spleens were assayed for both IgM (direct) and IgG (developed)
PFC. Although the size of the IgM responses in these
experiments were lower (Table 6) in all mouse strains
(except Balb/e) as compared with the responses on day 5
(Table 5), the ALG~tr©ated groups invariably showed a
severe depression in their responsiveness. In all cases
the suppression was highly significant and in the majority
of cases, the degree of suppression was greater than that
observed when mice were tested on day 5 (compare Tables 5
and 6), The IgG response in these mice was weak, as would
be expected at this time after the antigenic challenge (Table 7).
Nevertheless, in all strains where there was a measurable
IgG response in control groups, it was significantly
suppressed by AUG treatment (note C57B1» DBA/1 and C3H) •
However, in one instance (CBA) the ALG treatment caused a
small but statistically significant potentiation of the
primary IgG response. Hie significance of this potentiation
will be discussed later.
The serological tests performed on sera from the above
animals produced results which in general were consistent
with those obtained by the PFC assay. From the results
of haemagglutinating and haemolytic activities in sera
obtained on days k and 5 after antigenic challenge it is
-73a
TABLE 6 - THE EFFECT OF ALG OH THE PRIMARY IgM
IMMUNE RESPONSE OF DIFFERENT MOUSE
















































(a) 5*0 rag. NHIgG or ALG injected i.p. on days -4 and
-2| 3 x 10° SRBC given i.p. on day 0 and tooted
on day 4.
(b) Geometric mean with the limits of one standard error.
(c) Comparison between NHIgG and ALG groups.
(d) Number of slice in each group.
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fABLE 7 - THE EFFECT OF ALG QH THE PRIMaKY IgG










































(a) 5.0 rag. NHIgG or ALG injected i.p. on days -4 and
-2| 3 x 10° SRBC given i.p. on day O and tested
on day 4.
(b) Geometric mean with the limits of one standard error.
(c) Comparison between NTlIgG and ALG groups s P values
greater than 0.05 were considered not significant (N£»).
(d) Number of mice in each group.
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apparent that 2-raercaptoethanol treatment drastically reduced
the antibody tltres in all cases. This vas mora noticeable
in sera obtained on day k than in those obtained on day 5
(Tables 8—11). Moreover. ALG treatment in all instances
caused significant reductions in both baemagglutinin and
haemolysin responses. It is noteworthy that none of the
strains produced any significant amount of 2-mercaptoethanal-
resistant antibody following ALG treatment. In those cases
where the suppression of 2-ciercaptoethanol-resistant antibody
was not statistically significant, it was obviously due to
very poor response in the control groups.
offset of varying the antigen dose on the iataunoauppreaaive
ability of AIG
Groups of mice containing 3-8 mice were tested with
5 mg.of NIUgG or ALG intraporitoneally on days -4 and -2
and challenged with either 3 x 10; or 3 x 10^ SRBC by the
same route on day 0. Five days later they were tested for
splenic IgM PFC responses and serum antibody titres. The
results of PFC assays on these mice have been summarized
in Table 12.
In all instances the control groups (NlIIgG treated)
7
challenged with 3 at 10' SRBC gave a poorer response than
Q
those challenged with 3 x AO SRBC. When compared with
8
the response of mice challenged with 3 x 10 SRBC. it
7
appears that in all strains except B&lb/c. 3 x 10' RBC
-74a-
TABLe 8 - TIPS EFFECT of ALG oh THE PRIMARY HAi^HAGGLUXINXN























































































(a) 5.0 sag. NHlgG or ALG injected i.p. on days -4 and -2;
3 x 10® SRBC given i.p. on day O and tested on day 5.
(b) Arithmetic rawan £ 1 standard error.
(c) Comparison between NHIgG and ALG groups: p values
greater than 0.05 were considered not significant (N.S.).
(d) Observations from two different experiments.
(e) 2-Mercaptoethanol treatment.
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TABU! 9 - THE EFFECT OF ALG ON THE PRIMARY HAEMOLYSIN RESPONSE


















































































(a) 5,0 mg. NHXgG ALG injected i.p. on days -4 and -2j
3 x 10® SKBC given i.p, on day 0 and tested on day 5«
(b) Arithmetic mean x 1 standard error.
(c) Comparison between NHXgG and ALG groups: P values
greater than 0.05 were considered not significant (N.S.).
(d) Observations from two different experiments.
(e) 2-Mercaptoethanol treatment.
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TABLE 10 - THE EFFECT OF ALG ON THE PRIMARY lIAEMAGGLUriN:











































































(a) 5.0 rag, NHXgG or ALG injected i.p. on days -4 and -2|
3 x 10° SRBC given i.p. on day 0 and tested on day 4.
(b) Arithmetic mean _+ 1 standard error.
(c) Comparison between NHIgG and ALG groupst P values
greater than O.05 were considered not significant (M.S.).
(d) Observations from two different experiments.
(e) 2-Mercaptoethanol treatment.
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TABLS 11 - THE EFFECT OF ALG ON THE PRIMARY HASMOLYSIN RESPONSE






















































































(a) 5*0 mg. NHXgG or ALG injected i.p. on days -4 and -2;
3 x 10® SRBC given i.p. on day O and tested on day 4.
(b) Arithmetic moats j* 1 standard error.
(c) Comparison between NXUgG and ALG groups: P values
grater than 0.05 were considered not significant (N.S.).
(d) Observations from two different experiments.
(e) 2-Msrcapto©thanol treatment.
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are below the optimum dose and 3 x 10^ are above it (compare
Tables 5 and 6 with Table 12). It is also apparent from
the results in Table 12 that different strains varied
widely in their responsiveness to this antigen and the
variability was far more obvious in groups challenged
7
with the lower antigen dose, i.e. 3 x 10' SP.BC. However,
not much significance could be attached to these inter-
strain variations at this stage, since all the strains
were not tested at the same time. Also, the NHIgG pre-
treatmerit of mice might have modified their responsiveness
differently in different strains. Nevertheless, results
of better controlled experiments which will be described
in another section suggested that these interstrain
variations were genuine. Thus A/HeJ and C57BI mice
responded very poorly whereas Balb/c and DBA/1 gave very
high responses (see Appendix II).
From a comparison of NHIgG- and ALG-trested groups
it is evident that ALG treatment effectively suppressed
the lnsBune response of all the strains to both doses of
the entigen, although the degree of suppression generally
was greater in mice receiving the lower dose of the
antigen (Table 12).
The results of serological tests on these animals
have been summarized in Tables 13 and 1't. An increase in
the amount of antigen resulted in an increase in both
haemagglutinin and haemolysin titres in all strains of
-75a
TABLE 12 - THE EFFECT OF ANTIGEN DOSE ON THE SUPPRESSION OF PRIMARY





















































































(a) 5.0 sag. NHXgG or AEG Injected i .p. on days -* and -2;
3 x 107 or 3 x 10^ SRBC given i.p. on day 0 and tested on day 5.
(b) Geometric mean with the limits of one standard error.
(c) Comparison between NHIgG and ALG groups: P values greater
than 0.05 were considered not significant (N.S.).
(d) Number of mice in each group.








































































































































































































































































































































































































































































































































































































































raice treated with. NIIIgG. Ala o, an increase in the amount
of antigen resulted in higher titres of 2-mercaptoetiianol-
rea1stant haemagglut inin as veil as haemolysins. Never¬
theless the ALG pretreatment significantly suppressed the
total haemagglutinin and haemolysin responses in all mouse
strains challenged with both high and low antigen doses.
In addition, no significant amount of 2-mercaptoethanol-
rosiatant antibody was produced by ALG treated animals
in any of the mouse strains tested.
Effect of ALG on the secondary immune response of different
mouse strains
Groups comprising of 3-u mice vera sensitised with
8
3 x 10 SRBC and 3-^ weeks thereafter they received two
doses of 3 sag. each of NHIgG or ALG (id) two days apart.
Two days following this treatment, mice were challenged
8
with 3 * 10 SRBC and the PFC responses of spleens were
determined four days later. The results of these experiments
have been summarized in Tables 15 and lo.
Treatment with ALG effectively reduced the number of
both XgK and IgG PFC (possibly some IgA plaques too) In
all mouse strains, although the reductions were more
pronounced in some strains (e.g. Balb/c and DBA/l) than
in others (A/UeJ). The total haomagglutinin and haemolysin
responses were also significantly suppressed by the ALG
treatment in most mouse strains although the suppression
-76a-
TABLK 15 - TILE EFFECT OF ALG ON THE SECONDARY IgM
IMMUNE RESPONSE OF DIFFERENT MOUSE


















































































(a) 5.0 mg. NHIgG or ALG injected i.p. on days -4 and
-2; 3 x 10® SRBC given i.p. on day O and tested
on day 4 (mice were primed with 3 x 10® SRBC
3-4 weeks before the ALG treatment).
(b) Geometric mean with the limits of one standard error.
c) Comparison between NHIgG and ALG groups: P values
greater than 0.05 were considered not significant (N.S.
d) Number of mice in each group.
e) Observations from two different experiments.
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TABLE 16 - THE EFFECT OF ALG ON THE SECONDARY IfiO
(AND IgA?) IMMUNE RESPONSES OF DIFFERENT















































































(a) 5.0 Mg, NHXgG or ALG injected i.p. on days -4 and -2}
3 x 10** SRBC given i.p, on day O and tested on day 4
(mice were primed with 3 x 10® SR13C 3-4 weeks prior to
ALG treatment).
(b) Geometric mean with the limits of one standard error.
(c) Comparison between NHIgG and ALG groups,
id) Number of mice in each group.
(e) Observations from two different experiments.
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of the secondary circulating antibodies was not as striking
as the suppression of the primary responses (Tables 17 and 18).
The only exception in these experiments were C3H mice in
which the suppression of secondary haemagglutinin and
haemolysin responses by ALG treatment were variable.
Treatment of sera from these mice with 2-mercaptoethanol
caused very little reduction in the haemagglutinin titres
although the haemolysin titres were more susceptible to
this treatment. Furthermore, ALG treatment generally
was more effective in suppressing 2-mercaptoethanol-
resistant antibody titres (igG responses) than it was in
suppressing the total antibody titres. Again, in C3H
mice the suppression of 2-mercaptoethanol-resistant anti¬
bodies was variable.
In another series of experiments following the same
schedule of ALG treatment and antigen administration as in
the secondary responses described above, mice were tested
for the splenic PFC producing antibodies of different
immunoglobulin classes and subclasses. The results of
these tests have been summarized in Table 19*
It is apparent that ALG(ld) suppressed the responses
of Balb/c, DBA/1 and C3H mice in all antibody classes and
subclasses. However, in Balb/c mice the suppression of
IgG^b and XgA responses were not statistically significant.
The latter may be due to a wide variation in the inraune
response of individual mice in these immunoglobulin classes.
77a-
TABLE 17 - THE EirPECT QP ALQ ON THE SLCONQARY iiAEMA<^LUIXNIN


















5 13.8° £ 0.58
12.60 .+ 0.58

















6 8.50 + 0.22
8.33 ± 0.21






6 10.67 ± 0.21
10.67 * 0.21















6 10.50 ^ 0.22
7.83 ♦ 0.40















4 11.25 _+ 0.75
9.00 + 0.00






6 11.33 + 1.38
10.50 .+ 1.38













(a) 5*0 tag. NHIgG or ALQ injected i.p. on days -4 and -2;
3 x lO SRBC given i.p. on day 0 and tested on day 4
(mice were primed with 3 x 10® SRBC 3-4 weeks prior to
ALQ treatment).
b) Arithmetic mean _+ 1 standard error.
c) Comparison between NHIgG and ALQ groups: P values greater
than 0.03 were considered not significant (N.S.).
d) Observations from two different experiments.
e) 2-Mercaptoethanol treatment.
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TABLE 18 - THE EFFECT OF ALG ON THE SECONDARY HAEMOLYSIN





































6 9.17 + 0.54
7.00 + 0.36






6 11.40 + 0.24
6.83 + 0.31















6 8.33 + 0.21
6.33 + 0.33














b 7.75 + 0.25
5.50 + 0.29






6 6.67 + °'^2
3.83 + 0.87





b 7.75 + 0.48
5.50 + 0.29




(a) 5.0 mg. NHIgG or ALG injected i.p. on days -4 and -2}
3 x 10° SRBC given i.p. on day 0 and tested on day 4
(mice were primed with 3 * 10 SRBC 3-b weeks prior to
ALG treatment).
(b) Arithmetic mean _+ 1 standard error.
c) Comparison between NHIgG and ALG groups; P values greater
than 0.05 were considered not significant (N.S.).
d) Observations from two different experiments.
e) 2-Mercaptoethanol treatment.
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In A/HeJ mice, ALG treatment resulted in a suppression of
all antibody claae.a oxo.pt IgG^, ohich »a. .lightly
enhanced. The significance of this enhancement will be
discussed later (Table 19).
Effect of different ALQ preparations on the immune response
laiiiiM^— « ■IIMI II ■ ■ ■ ■» '•IM'II* II » ■»—aweW —rnmr n ■■ n «' mmutmmm——
of CBA mice
The effect of four AUG preparations from individual
horses were studied in CBA mice. These included the
preparation (id) used in the bulk of these studies, while
the other three preparations were raised in different
horses using different schedules of immunization with
thymocytes from Swiss albino mice (see Table 2).
Groups containing k-5 animals were treated with 5 mg.
of NHIgG or different ALG preparations on days and -2
8
and were challenged on day 0 with 3 x 10 SRBC. Five
days after the challenge the spleens from these mice wore
assayed for their PFC responses. In these experiments
both IgM and IgG responses were measured.
The results of IgM (direct) and IgG (developed) PFC
in the spleens of various groups of animals have been
listed in Table 20. Although the effectiveness of
individual ALG preparations to suppress IgM PFC responses
varied, they all significantly suppressed this response.
It should be noted that the IgG responses were more readily
suppressed by the same ALG preparations than the IgM responses.
78a-
TABLB 19 - THE EFFECT OF ALQ ON THE SECONDARY IMMUNE RESPONSE OF
















































































































thgiven i.p. on day O and tested on day 4 (mice were primed wx
3 x 10® SRBC 3-4 weeks prior to ALG treatment).
(b) Geometric mean with the limits of one standard error.
(c) Comparison between NHIgG and ALG groups: P values greater than
0.05 were considered not significant (N.S.).
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TABLE 20 - THE EFFECT OF VARIOUS ALQ FRBPARATIONS ON
THE IMMUNE RESPONSE OF CBA MICE AGAINST
SHEEP ERYTHROCYTES®
ALG Plaque Forming Cells Per Spleen1*




















(a) 5*0 sag. NlIIgG or ALG injected i.p. on days -4 and
-2; 3 x 10° SRBC given i.p. on day O and tested
on day 5.
(b) Geometric mean with the limits of one standard error.
(c) Comparison between NHJgG and ALG groups.
(d) Number of mice in each group.
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However, the preparations least effective in suppressing
the IgM responses (e.g. AJLG3) were likewise least effective
in suppressing the IgG responses. Conversely, the pre¬
parations most effective at suppressing the IgW responses
were also very effective at suppressing IgG responses
(e.g. ALG Id).
The results of serological tests on these sera closely
followed the pattern observed in the PFC assays. Namely,
the antiserum least effective at suppressing PFC responses
was also relatively less effective at suppressing haemag-
glutinin and haemolysin responses (Table 21). Nevertheless,
all the ALG preparations significantly suppressed the
circulating antibody formation.
effect of ALG prepared from successive bleeds from a single
horse
In these experiments groups of CBA mice (*»-5 animals
per group) were pretreated with NIIIgG or ALG prepared from
different bleeds from a single horse at different stages
of immunization (see Table 2). The dose and schedule of
ALG administration and antigenic challenge were similar
to those described above. The results of PFC assays on
spleens from these mice 5 days after antigenic challenge,
have been summarized in Table 22.
All ALG preparations except la (obtained on day 21
after a single injection of thymocytes) significantly
79a-
TABLC 21 - THE EFFECT OF VARIOUS ALG PREPARATIONS ON THE






































































(a) 5.0 mg. NHIgG or ALG injected i.p. on days -4 and -2;
3 x 10s SRBC given i.p. on day 0 and tested on day 5*
(b) Arithmetic mean _+ 1 standard error.
(c) Comparison between NHIgG and ALG groups.
(d) Number of mice in each group.
(e) 2-Mercaptoethanol reduced.
-79b
TABLE 22 - THS RELATIONSHIP BETWEEN THE ABILITY OF AJLG TO
SUPPRESS Tlm IMMUNE RESPONSE OF CBA MICE TO
SHEEP ERYTHROCYTES AND TUB HYPERIMMUNIZATION
OF THE ALO DONOR*
ALG Plaque Forming Cells Per Spleen*3





















(a) 5*0 tag. NHXgG or ALG injected i.p. on days -h and
-2; 3 x loS SRBC given i.p. on day O and tested
on day 5.
(b) Geometric mean with the limits of one standard error.
(c) Comparison between NILIgG and ALG groups t P values
greater than 0.05 were considered not significant (N.S.).
(d) Number of mice in each group.
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suppressed the IgM response, although the degree of suppression
varied from one preparation to the other. It should be noted
that the Immunosuppressive capacity of the ALG preparations
Increased with the number of Immunizing injections of the
donor horse. The differences between the immunosuppression
caused by different ALG preparations was significant in most
cases ( la<0.02 lb(n.s.) lc«0.0Ql IdO.OOl la ). From the
data on Table 22 it is also apparent that IgG responses
were relatively more susceptible to suppression by all
ALG preparations than the IgM responses. It should be
pointed out that ALG preparation la significantly suppressed
the IgG PFC response but not the IgM response.
The serological data from the above experiments is
recorded in Table 23. This data strengthens the findings
obtained with the PFC assays.
Recovery of the immunocompetence after ALG treatment
Groups containing a minimum of four mice were treated
with ALG(id) on days -4 and -2 and challenged on day 0 with
&
3 x 10 SRBC. Thereafter the mice were bled at various
intervals from the retro-orbital sinus. These mice were
8
rechallenged at 13-17 weeks with 3 x 10 SRBC and exsanguinated
6 days later. All the sera were tested for haemagglutinating
antibodies.
The results of one such experiment in CBA mice have
been summarized in Figure 9. It is apparent that following
-80a
TABLE 23 - TIBS RBLAHOflSHIP BETWEEN THE ABILITY OF ALG TO
SUPPRESS TitE CIRCULATING ANTIBODY RESPONSE OF
CBA MICE TO SHEEP BP TTl OVOCYTES AND THE'
HYPERiMMUNIZATION OF THE ALG DONOR**
ALG
Prep.






































































(a) 5*0 mg. NIIIgG or ALG Injected i.p. on days -4 and -2;
3 x 10® SRBC given i.p. on day 0 and tested on day 5«
(b) Arithmetic mean + 1 standard error.
(c) Comparison between NHIgG and ALG groups: P values
greater than 0.05 were considered not significant (N.S.).












































ALG pretreatment the primary immune response to SRBC remained
depressed for at least three months. However, this schedule
of ALG treatment did not inhibit the sensitization of these
animals* because a subsequent challenge with the antigen
resulted in an immune response comparable with that in the
control animals, These findings were confirmed by a similar
experiment in C57B1 mice (Figure 10).
IMMUNE RESPONSE TO PNEUMOCOCCAL POLYSACCHARIDE (SSS-III)
Effect of standard ALG(id) on the immune response of different
strains of mice to SSS-III
Mice (4-6 per group) were injected intraperitoneally on
days -4 and -2 with 0.25 ail. of 2 g. per cent (5 mg.) NHIgG
or ALG. Two days later (day 0) they were challenged intra¬
venously with lfig. of purified SSS-III antigen. Five days
after antigenic challenge the animals were exsanguinated
and the spleens removed for PFC assays. The results of
these assays are recorded in Table 24.
The magnitude of the immune response in different
mouse strains varied considerably; the A/HeJ and C57B1
mice responded very poorly to this dose of the antigen
whereas Balb/c, CDA and C3H mice gave relatively higher









































TABLE 24 - EFFECT OF ALG ON THE PRIMARY IMMUNE RESPONSE











































(a) 5.0 tag. NHIgG or ALG injected i.p. on days -4 and -2;
l.Ofig. SSS-III given i.v. on day 0 and tested on day 5*
(b) Geometric mean with the limits of one standard error.
(c) Comparison between NHIgG- and ALG-treated groups.
(d) Number of mice in each group.
(e) Observations from two different experiments.
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at the same time, it is not possible to make an interstrain
comparison from these results. Nevertheless, the inter-
strain variations were confirmed in another series of
experiments and the relatively poor responsiveness of
A/lieJ and C57B1 mice compared with that of Balb/c mice
was established using a suboptimal dose (0.1(ig.) of SSS-III
antigen (see Appendix XX). However, in all strains of mice,
the immune response to this dose (l.Opg.) of SSS-XXX was
significantly suppressed (p values of <0.02 - <0.001) by
ALG pre treatment.
The serum agglutinin titres in these mice were also
significantly suppressed by the ALG treatment in most mouse
strains, although the reduction in the agglutinin titres was
not as marked in some strains as in others (note A/lieJ,
Balb/c and DBA/1 in Table 25). the suppression in A/HeJ
mice was Just below the significance level (P value Just
over 0.05) and the suppression in C57B1 mice was not at
all significant. The latter may be due to very poor
agglutinin response of this mouse strain. The suppression
of the agglutinin responses in CBA and C3H mice was very
marked and highly significant (P values less than 0.001).
Effect of varying antigen dosage on the suppression of the
response by ALG
Groups of mice (3-o mice per group) were treated with
MlilgG or ALG and challenged with 0.1 or 3ng. of SSS-XXX
-82a
TABLE 25 - THE EFFECT OF ALG ON THE PRIMARY 1IAEMAGGLUTIN1N










A/HeJ 5 5.20 _+ 0.20 5 4.20 ♦ 0.22 N.S.




























C3H 4 6.50 ± 0.29 6 1.50 ♦ 0.34 <0.001
(a) 5.0 mg. NHIgG or ALO injected i.p. on days -4 and -2;
l.Ofig. SSS-IXI given i.v. on day O and tested on day 5 •
(b) Arithmetic mean _+ 1 standard error.
(c) Comparison between NHIgG- and ALG-treated groups:
P values greater than 0.05 were considered not
significant (N.S.).
(d) Observations from different experiments.
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(the schedule and the dose of ALG were described in the
preceding experiments). Five days later the animals
were sacrificed for splenic PFC and serum agglutinin
assays. The results of these experiments have been
documented in Tables 26 and 27.
It is apparent that lower doses of the antigen (O.lpg.)
failed to give a significant response in some strains (C37BI
and DBA/1 in Table 26) or elicited only very small response
(e.g. A/HeJ and DBA/1 mice). However, in the strains in
which there was a satisfactory response to this dose of
antigen, it was signifieantly suppressed by ALG pretreatment
(all strains except C57BI and DBA/1 in Table 26). In
addition, the response to SSS-TII was invariably
suppressed by ALG in all strains and, in all cases, the
suppression was statistically significant. It should,
however, be noted that in all cases the degree of suppression
in mice given SSS-III was less marked than that in mice
given 1.0;ig. SSS-III (compare Tables 2h and 26). The
serum agglutinin responses to both antigen doses were
suppressed by the ALG treatment in all mouse strains, with
the exception of C57BI and DBA/1 mice. In the latter
two strains the ALG failed to suppress significantly the
agglutinin response to the lower antigen dose. ALG also
failed to suppress the agglutinin response to 5pg» SSS-III
in A/HeJ mice andin one experiment it failed to suppress
the response of Balb/c mice to O.log. SSS-III; the P value
-83a-
TADLE 26 - THE EFFECT OF ANTIGEN DOSE ON THE SUPPRESSION OF THE
PRIMARY OlMUNK RESPONSE DY ALG IN DIFFERENT MOUSE


























































































(a) 3.0 mg. NHIgG or ALG injected i.p. on days -4 and -2| 0.1
or 5*0pg. SSS-III given i.v. on day O and tested on day 5»
(b) Geometric mean with the limits of une standard error.
(c) Comparison between NHIgG- and ALG-treated groups 2
P values greater than 0.03 were considered not significant (N.S.)
(d) Observations from two different experiments.
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TABLE 27 - THE EFFECT OF ANTIGEN DOSE ON THE SUPPRESSION OF
THE PRIMARY HABMAGGLUTININ RESPONSE BY ALG IN














































































5.0 5 5.00 + 1.00 5 neg <0.005
c3H
0.1 4 6.25 + 0.25 4 2.75 + 1.03 0.02
5.0 5 6.40 + 0.24 7 1.57 + °«37 <0.001
(a) 5.0 mg. NHIgG or ALG injected i.p. on days -4 and -2j 0.1
or 5.0pg. SSS-III given i.v. on day 0 and tested on day 5*
(b) Arithmetic mean _+ 1 standard error.
(c) Comparison between NHIgG- and ALG-treated groups:
P values greater than 0.05 were considered not
significant (N.S.).
(d) Observations from different experiments.
-84
in the latter case was only marginally higher than the
significance level (Table 27).
effect of different ALG preparations on the immune response
to SSS-III
Groups of mice containing 4-5 animals per group were
injected intraperi toneally with 5 tag. of NHXgG or individual
ALG preparations on days -4 and -2 and were challenged on
day 0 with l.Opg. SSS-III antigen. The spleens from these
mice were tested for the PFC response on the 5th day after
the antigenic challenge and the sera were tested for
agglutinating antibodies.
The results of the splenic PFC responses have been
summarized in Table 28. It will be observed that only ALG
preparation Id produced a suppression of anti-SSS-III response
in CBA mice which was statistically significant. Although
suppression was caused by preparations 2 and 3# the p values
in these instances were marginally outside the significance
limits. Indeed one preparation (ALG 4) produced a significant
increase in the number of PFC per spleen. However, when
the results were expressed as the number of PFC per 10°
nucleated spleen cells (see Table 29) It appears that ALG
preparations 2 and 3 significantly suppressed the response.
Furthermore, the enhancement caused by the ALG preparation 4
proved to be statistically non-significant when the PFC per
10° nucleated spleen cells were considered.
-84a-
TABL& 28 - THE EFFECT OF VARIOUS ALG PREPARATIONS OS THE IMMUNE
























































(a) 5.0 tag. NHIgG or ALG injected i.p. on days -4 and -2;
l.Opg. SSS-III given i.v. on day 0 and tested on day 5.
(b) Geometric mean with the limits of one standard error.
(c) Comparison between NHIgG- and ALG-treated groups 2
P values greater than 0.05 were coneidered not
significant (N.S.).
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TABLE 29 - THE EFFECT OF VARIOUS ALG PREPARATIONS ON THE IMMUNE




























































(a) 5»0 mg. NHXgG or ALG injected i.p. on days -4 and -2;
1.0 |*g. SSS-III given i.v. on day 0 and tested on day 3•
(b) Geometric mean with the limits of" one standard error.
(c) Comparison between NHIgG- and ALG-treated groups:
P values greater than 0.05 were considered not
significant (N.S.).
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In contrast all four preparations significantly
suppressed the plaque forming cell response to SSS-III
in Balb/o mice. This was statistically significant
both at the FFC per spleen (Table 28) and the PFC per
10^ nucleated spleen cell levels (Table 29).
The circulating antibody levels were also suppressed
by the ALG treatment but the effect was probably less
dramatic than observed in the PPC assays (Table 30).
Nevertheless a significant suppression of agglutinin
responses in Balb/c mice was obtained with all ALG pre¬
parations while only preparation 4 failed to significantly
suppress the agglutinin response in CBA mice.
affect of ALO prepared from successive bleeds from a
single horse
■4
In these experiments groups of animals (4-5 mice per
group) were pretreated with four different ALG preparations
Isolated from successive bleeds obtained from a single horse
at various stages of immunisation (see Table 2). The
control animals received 5 NHIgG whereas the test ones
were given the same quantity of ALG on days -4 and -2.
The mice in all groups received 1.0|Jg. SSS-III on day 0.
From the results of FFC assays carried out on day 5
after challenge it is apparent that with the exception of
ALG preparation la (obtained after a single injection of
the horse) all preparations significantly suppressed the
-85a-
TAJBLB 30 - THE EFFECT OF VARIOUS ALG PREPARATIONS ON THE
HABlAGGLUTININ RESPONSE OF CBA AND Balb/c MICE






mice Log2 Tit re13 Prep.No. No. ofmice Log2 Titre
Balb/c
4 8.50 + 0.29 Id 5 4.60 _£ 0.24 <0.001
4 7.50 + 0.29 2 4 6.25 ± 0.25 <0.02
4 7.50 + 0.29 3 4 5.75 + 0.48 <0.02
4 8.5O + 0.29 4 5 6.40 0.4 <0.005
CBA
4 6.25 + 0.25 Id 4 2.50 ± O.50 <0.001
4 6.25 + 0.25 2 4 3.75 + 0.25 <0.001
5 6.80 + 0.37 3 5 5.20 + 0.20 <0.01
5 6.60 0.24 4 4 5.50 + 0.64 N.S.
(a) 5.0 rag. NHIgG or ALG injected i.p. on days -4 and -2;
1.0 ng. SSS-III given i.v. on day O and tested on day 5*
(b) Arithmetic mean _+ 1 standard error.
(c) Comparison between NHIgG- and ALG-treated groups:
P values greater than 0.05 were considered not
significant (N.S.).
-85b-
fAff6., 31 - EFFECT OF HYPER IMMUNIZATION OF ALS DONOR ON THE ABILITY
OF THE ALG TO SUPPRESS TiTe IMMUNE RESPONSE OF Balb/c AND

















































(a) 5.0 sag. NIIIgG or ALG injected i.p. on days -4 and -2;
l.Ofig. SSS**XXX jfiv©n X «v• on d&y O ondl tiostjod on d&y 5 •
(b) Geometric mean with the limits of one standard error.
(c) Comparison between NHXgG— and ALG-treated groups:
P values greater than 0.05 were considered not
significant (N.S.).
—QJ—
PFC response of CBA mice to l.Opg. SSS-III (Preps. lb, lc
and Id in Table 31)* Similarly, preparations lb-Id caused
a significant suppression of tbis response in Balb/c mice.
In contrast preparation la caused a slight enhancement of
the anti-SSS-III response though this was not statistically
significant. It should be noted that there was a gradual
increase in the immunosuppressive capacity of ALG with
hyperimmunization of the horse.
The data from the same experiment have been recorded
as PFC per 10(> nucleated spleen cells in Table 32.
Expressed in this form the suppression of anti-SSS-III response
by various ALG preparations in both CBA and Balb/c mice is
more obvious. However, ALG la still fails to show any
immunosuppressive effect.
The results of serological tests on these mice were
somewhat different. The ALG preparation lb failed to
suppress significantly the agglutinin response in both CBA
and Balb/c mice, whereas all other preparations suppressed
significantly the anti-SSS-III agglutinin response in both
Balb/c and CBA mice (Table 33)•
i^ffect of an alternative ALG treatment schedule on its
immunosuppressive capacity
The results of studies on the effect of ALG on SSS-IIX
responses presented in the previous sections contrast markedly
with the observations of Baker and his colleagues (Baker,
-86a-
TABLE 32 - THE EFFECT OF HYPHRIMMHNIZATION OF ALS DONOR ON THE
ABILITY OF THE ALG TO SUPPRESS THE IMMUNE RESPONSE
























































(a) 5.0 tag. NHIgG or ALO injected i.p. on days -4 and -2|
l.Opg. SSS—III given i.v. on day 0 and tested on day 5*
(b) Geometric mean with the limits of one standard error.
(c) Comparison between NHIgG- and ALG-treated groups*
P values greater than 0.05 were considered not
significant (M.S.).
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TABLE 33 - THE EFFECT OF HYPKRIMMUNIZATION OF ALS DONOR ON THE
ABILITY OF THE ALG TO SUPPRESS THE IIaEMaGGLUTIKXN







Mice Logg Titreb Prep.No. No. ofMice Log2 Titre
Balb/c
4 7.50 + 0.29 lb 5 6.80 ♦ 0.37 N.S •
4 7.50 * 0.29 1c 5 5.60 + 0.24 <0.005













6.25 + 0.25 lb 5 3 .60 _+ 1.01 N.S.












(a) 5.0 mg. NHIgG or ALG injected i.p. on days -4 and -2}
1.0 fig. SSS-XIX given i.v. on day O and tested on day 5.
(b) Arithmetic mean 1 standard error.
(c) Comparison between NHIgG- and ALG-treated groups:
P values greater than 0.05 were considered not
significant (N.S.).
* Observation from two different experiments.
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Barth, Stashak and Arasbaugb, 1970} Baker, Stashak, Amsbaugh,
Prescott and Barth, 1970) who demonstrated that their anti-
lymphocyte antibody potentiated rather than suppressed
the immune response to SSS-III antigen. It was conceivable
that these contrasting observations could be attributed
to differences in the ALO treatment schedules used. In
order to test this possibility groups of Balb/c alee were
treated with 5 rag. of NHIgG or ALG preparations and challenged
with l.Opg. SSS-III following the schedule described in the
preceding sections. Other groups were treated with 5 Big.
of the same NHXgG or ALG preparations 15-20 minutes prior
to antigenic challenge with an identical dose of SSS-IXI
(a schedule similar to that adopted by Baker and his
colleagues). The animals were sacrificed five days after
the antigenic challenge and splenic PFC and circulating
agglutinin responses measured. In addition groups of
CBA mice were treated with NHIgG or ALG on day -8 and -o
or -k and -2, challenged with SSS-III on day 0 and their
response measured on day 5» The results obtained are
recorded in Tables 3^-3o.
As previously noted (see Balb/c in Tables 31 and 32)
all ALG preparations tested suppressed the PFC response of
Balb/c mice to SSS-III if administered on days -U and -2
prior to antigenic challenge. In contrast however, if
their administration was delayed until just prior to anti¬
gen administration only ALG Id was effectives Indeed
-87a-
tablb 34 - the effect of alternative anti-lymphocytic antibody
treatment schedules on the immune response of mice


















































































5 mg. ALG injected i.p. on days -8, -6, -4, -2 or on
day 0} l.Opg. SSS-III given i.v. on day 0 and tested
on day 5»
Geometric mean with the limits of one standard error.
Comparison between NEHXgG— and ALG—treated groupst
P values greater than 0.05 were considered not
significant (N.s.).
Number of mice in each group.







alg 2 potentiated the response although this potentiation
was not statistically significant (Table 34). lbs data
on PFC per 10 J nucleated spleen cells recorded in Table 35
indicate a slightly better suppression by thevarious aLO
preparations. ALO preparations Id and 3 significantly
suppressed the SS8-III response even when administered
Just before the antigen; preparations 2 and 4 still
remained ineffective.
Incidentally* it should also be noted (see following
section) that ALO Id was effective at suppressing PFC
response of CBA mice when administered on days -8 and -6
before the antigen* although the effect was not as marked
as that when the ALG was administered on days -4 and -2
(Table 35).
The results of serological tests recorded in Table 36
were again slightly Inconsistent with those of PFC assays.
In this test ALO preparations Id and 2 failed to suppress
the agglutinin responses* whereas the remaining preparations
were significantly effective at suppressing agglutinin
titres. It should be noted that the suppression by ALG Id
administered cm days -8 and -a before the antigen was Just
outside the significance limits (Table 36).
Tngaunocompetence of ALO treated mice reconstituted with
various syngeneic lymphoid cell populations
These preliminary experiments were performed to establish
-88a-
TABLS 35 - the effect of alternative anyi-lymphocytic antibody
tfteatment schedules ON THE immune response of mice







































































(a) 5 rag. ALG injected i.p. on days -8, -o, -4, -2 or on day 0|
l.Opg.
(b) Geometric mean with the limits of one standard error.
(c) Comparison between NHIgG- and ALG-treated groups: P values
greater than 0.05 wore considered not significant (N.S.).
* Tested in CBA mice; all other observations were made
in Balb/c mice.
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TABLE 36 - THE EFFECT OF ALTERNATIVE ALG TREATMENT SCHEDULES















-4 J -2 4 8.50 + 0.29 5 4 .60 J; 0.24 <0.001
0 4 8.25 ± 0.48 5 8.80 + 0.20 N.S.
Id*
-4; -2 3 6.25 + 0.25 4 neg «0.001
—8; —6 3 6.33 * 0.33 5 5.40 + 0.24 N.S.
2
-4; -2 4 7.50 + 0.29 4 6.25 ♦, 0.25 0.02
0 4 8.75 ♦ 4 8.75 + 0.25 N.S.
3
-4 i -2 4 7.50 + 0.29 4 5.75 ± 0.48 0.025
0 4 8.75 + 0.48 4 7.25 + 0.25 0.05
4
-4; -2 4 8.50 + 0.29 5 6.40 + 0.40 0.005
0 4 8.25 + 0.48 5 9.80 + O.80 N.S.
(a) 5 rag, ALO injected i.p. on daye -8, -6, -4, -2 or on day O;
l.Opg. SSS-IXI givon i.v. on day 0 and tested on day 5»
(b) Arithmetic mean _+ 1 standard error.
(c) Comparison between NHIgG- and ALG-treated groups: P values
greater than 0.05 were considered not significant (N.S.).
* Tested in CBA mice; all other observations were made
in Balb/c mice.
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the cellular basis of the immunological deficiency in the
mice treated with ALG preparation Id. In these studies
CBA mice were injected intraperitoneally on days -8 and
"6 with 0.25 ml. of 2 g. per cent (5 mg.) NHXgG (group A)
or ALG (groups B-E) preparation. Four days later (i.e.
on day -2) the mice were injected intravenously with
either Eagle*s medium alone (groups A and B)f syngeneic
thymocytes (group C), syngeneic bono marrow cells (group D)
or syngeneic spleen cells (group E). The number of lymphoid
cells injected in each group is indicated in Table 37.
Two days after cellular reconstitutlon (day 0), all the
mice were challenged with l.Opg. SSS-III antigen. The
animals were sacrificed five dayo later and the splenic
PFC responses were measured.
It is apparent from the data presented in Table 37
that mice receiving Eagle*s medium alone (group B) after
ALG treatment were only able to mount a meagre response
to SSS-III. However, reconstitutlon with normal thymocytes
(group C), bone marrow cells (group D) or spleen cells
(group E) resulted in a partial recovery of the capacity















































































































































IMMUKE RESPONSE TO DOVTNB SERUM ALBUMIN (BSA)
effect of different ALG preparations on the Immune response
to BSA
Groups containing 5-u CBA mice were injected intra-
peritoneally with 0.25 nl. of 2 g. per cent (5 mg.) BiilgG
or ALG on days -4 and -2 and challenged intraperitoneally
with 1 sag* alum-precipitated BSA. Mice were exsanguinated
on day 21 after the challenge and the sera were collected.
Sera from individual mice were tested for antibodies against
BSA. The results of these tests have been summarised in
Table 33.
It is clearly apparent that all ALG preparations tested
were able to suppress the primary immune response to BSA.
This included preparation la Isolated from a bleed obtained
after immunization with a single thymocyte inoculum.
However, it can be seen that the degree of suppression varied
from one preparation to the other. Also, from the comparison
of the degree of suppression caused by ALG from different
bleeds, it is apparent that the ability of these preparations
to suppress anti-BSA response increased with hyperimmunization
of the horse (compare ALG preparations la-Id in Table 38).
It should, however, be noted that none of the ALG preparations
significantly altered the relative binding affinity of anti¬
body produced by these animals.
-90a
TABLE 38 - THE EFFECT OF DIFFERENT ALG PREPARATIONS ON THE














NHIgG 5 6.16(5.66—6,69) 37.0 + 4.7 Z
ALGla 6 1.99(1.76-2.25) <0.001 35.4 +3.2 N.S.
ALGlb 6 1.66(1.39-1.99) <0.001 28.3 ± 1.4 N.S.
ALGlc 6 0.81(0.61-1.07) <0.001 35.5 +2.8 N.S.
ALGId 6 0.80(0.54-1.19) <0.005 30.9 ± 3.1 N.S.
ALG2 5 2.50(2.25-2.78) 0.001 39.0 + 4.4 N.S.
ALG3 6 1.62(1.48-1.77) <0.001 30.6 + 2.3 N.S.
ALG4 6 1.11(0.93-1.33) <0.001 33.3 + 3.0 N.S.
(a) 5 mg. NMIgG or ALG injected i.p. on daya -4 and -2;
1.0 Bg. alum-BSA given i.p. on day O and tested on
day 20.
(b) Geometric mean with the limits of one standard error.
(c) Comparison between NHIgG- and ALG-treated groups:
P values greater than 0.05 were considered not
significant (N.S.).




Observations made over the last decade have unequivocally
demonstrated the effectiveness of ALG In suppressing allograft
immunity. Xn addition various other cell mediated responses
have been shown to be suppressed by ALG treatment (see the
Introduction). It has been postulated that ALG caused
the suppression of cell mediated immunity by eliminating
or inactivating population of cells which are mainly
implicated in the homograft and other cell mediated immune
reactions (reviewed in Introduction).
The earlier findings of Lance and Batchelor (1963)
indicated that the allograft response of mice could be
suppressed by anti-lymphocytic serum while their antibody
response to the same transplantation antigens was unaffected.
On the basis of these experiments and some others in which
the suppression of humoral immune response to Salmonella
typhi •H* antigen and in certain cases the immune response
to BSA seemed refractive to the action of anti-lymphocytic
serum, it was suggested that this reagent could selectively
suppress cell mediated immunity by discriminately depleting
the thymus-derived cells (Levey and Medawar, 1966a;
Lance and Batchelor, 1968; Lance, 19o8a,b). The role
of thymus-derived lymphocytes in cell mediated immune
reactions has already been stressed in the introductory
part of this thesis. It should also be added that the
recirculating pool of long-lived small lymphocytes which
have been shown to be preferentially depleted by the ALG
92-
treatment (Denrnan, Denxaan, limb ling, 1968; Taub, 19^9;
i£verett, Schwartz, Tyler and Perkins, 1970) have also
been demonstrated to be chiefly derived from the thymus
(Govons and McGregor, 1965 J Doenhoff, 1971 )•
In contrast, a number of observations have indicated
that certain humoral immune responses could be suppressed
by anti-lymphocytic antibody. This suppression could
possibly be attributed to the elimination of thymus-derived
lymphoid cell populations which have in the past decade
been shown to play a vital role in the initiation of an
immune response to a variety of antigens (Taylor, 1969;
Roitt, Greaves, Torrigiani, Qrostoff and Playfair, 1969;
Playfalr, 1971? Miller, Basten, Sprent and Cheers, 1971).
In the course of the early attempts to suppress the
humoral immune responses by the anti-lymphocyte serum
treatment, it was observed that adult thymectomy potentiated
the immunosuppression caused by ALS (jeejeebhoy, 1965a,b;
Monaco, Wood and Russell, 1965{ Leuchars, Wallie and Davies,
1968). These observations further strengthened the view
that ALG could cause the suppression of different immune
responses by eliminating, inactivating or interfering with
the function of the thymus-derived cell population.
The site of action of ALG was investigated by Martin
and Miller (1968). These authors concluded that ALS
exerted its insnunosuppressive effect in humoral immune
systems by eliminating the thymus-derived antigen reactive
-93-
cella . The so observations were confirmed and further
extended by those of Mitchison (1970).
The observations led to the widespread belief that
anti-lymphocytic sera could selectively eliminate the
thymus-derived lymphoid cell populations. As a result
these reagents have been frequently used as selective
*T* cell depletors in a number of immunological experiments
of theoretical and practical importance.
In order to confirm and extend that anti-lymphocytic
antibodies could suppress humoral immune responses and
also whether this reagent exerted its immunosuppressive
effect on humoral responses entirely via thymic cell
population or whether other lymphoid cells were also
implicated, the immunosuppressive effects of anti-lymphocytic
antibodies were studied. The choice of antigens against
which the immune responses have been studied was made on
the current knowledge of cellular involvement in the immune
response against these antigens. These included sheep
erythrocytes, pneumococcal polysaccharide and bovine serum
albumin.
It is now well established that to achieve an optimal
immune response to sheep erythrocytes, it is essential
that the animal in which this antigen is administered
should have both the thymus-derived •T* cell population
and the antibody producing ,B* cell population (Miller,
Mitchell and Veiss, 1967» Mitchell and Miller, 1968).
-94-
It is also known that thymus-derived cells do not secrete
any antibody (Davies, Leuchars, V/allis, Harchant and
Elliot, 1967)» although they may produce and exhibit
small amounts or antibody on their surface (Greaves,
1970} Bankhuret, Warner and Sprent, 1971I Marchalonis,
Cone and Atwell, 1972). Furthermore, it has been shown
that the antibody producing cells belong to a population
of colls which origin&to from the bone marrow and develop
to maturity independent of the thymic influence (Miller
and Mitchell, 1968).
The other antigen pneumococcal polysaccharide which
was employed in a large section of these studies was
chosen for its ability to elicit an immune response at
least in CBA mice without the apparent participation of
thymus-derived cells (Humphrey, Parrott and deSousa, 19^4 {
Davies, Carter, Leuchars, Wallis and Dietrich, 1970}
Howard, Christie, Courtenay, Leuchars and Davies, 1971)*
In addition the effect of ALG on the immune response
against BSA was also studied in a limited number of experi¬
ments. This was to establish the effect of this reagent
on the immune response of another antigen which requires
the participation of the thymic lymphoid cell population
(Taylor, 1969).
Apart from studying the effect of ALG on the intsoune
response to several antigens, it was also felt necessary
to study this in several strains of mice. This was based
95
on the strain variations observed in both rata and mice
in the responsiveness to different antigens as well as In
the effectiveness of ALG to suppress the immune response
to certain antigens (James, Pullar and James* 1969j James
and Milne, 1972).
Prom the results of experiments with sheep erythrocytes
it is obvious that ALG Id was adequately effective in
suppressing the primary XgM (direct FFC) response to an
optimal dose (3 x 10®) SRBC in all mouse strains tested
(Figure 11 and Table 7)* This is consistent with the
previous findings reported by several workers (Earth and
Southvorth* 19681 Dauns, Lietorman and Frenkel* 19691
Argyrie and Plotkin, 1970). However, the effect of
this ALG preparation on the primary IgG (developed PFC)
response varied from strain to strain. In strains of
mice where the control groups gave a measurable IgG response
(C37B1, DBA/1 and C3H in Table 7 and Pigure 11), the response
in ALG treated animals was significantly suppressed. (PO.OGl
in Pigure 11). It should be noted that the differences
between the response of NHIgG- and ALG-treated groups
(i.e. the suppression achieved by ALG treatment) was
generally more apparent when the PFC per 10^ cells (as
apposed to PFC per spleen) were considered. This was
due to a gross increase in the number of splenic nucleated
cells following ALG treatment. Similar hyperplasia of
the spleens in ALG-treated animals has been reported by
-95a-
FIGURE 11
EFFECT OF ALG ON THE PRIMARY IMMUNE RESPONSE IN DIFFERENT
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various other workers (Taub and Lance* 19o8j Denman and
Frenkel, 19obb; Marshall and Knight, 1989; Simpson and
Nehlsen, 1970; Rodriguez-Paradisi, Thierfelder, GStze,
Bulitz and Beil, 1970).
In contrast, in those strains of mice in which there
was very little or no measurable IgG response in the NHIgG-
treated groups, aug treatment exerted an adjuvant-like
effect (a/Hej and CBA in Table 7). However, this augment¬
ation by ALG was only significant in CBA mice (Table 7).
This augmentation in the immune response to SRBC may be
due to variations in the relative amounts of individual
IgG subclasses evoked following the antigenic challenge.
In this respect it is relevant to recall the findings of
Anderson and her colleagues who reported a similar enhance¬
ment by ALG of the IgG^ and anti**i5RBC response in
CBA mice (Anderson, Dresser, Iverson, Lance, Vortis and
Zebra, 1972). It is possible that the primary response
to SRBC in certain strains, e.g. CBA and A/HeJ, are mainly
in IgG^ and XgG^ classes. The results of experiments
to further investigate the effect of ALG on various
immunoglobulin classes and subclasses will be discussed
later.
Further experiments were designed to investigate the
effect of ALG on the immune response to increasing doses
of antigen. It has been reported that an increase in the
dose of antigen could overcome the immunosuppressive
97
effects of ALG treatment (Lance* l£?70a,b; Argyris and
Plotkin, 1970)• It could be postulated that ALG failed
to suppress the immune response to higher antigen doses
because an Increasing dose of antigen could by-pass the
need for the thymic cell participation in certain immune
responses (Sinclair and Elliott, 1968? Taylor and Vortis,
1968| Playfair and Purvcs, 1971). However, contrary to
the findings of Lance (l970a,b) ami Argyrie and Plotkin
(1970) the present results indicate that increasing the
dose of antigen (3 x 10? to 3 * 109 SRBC) did not completely
overcome the immunosuppressive effects of the ALG in any
of the mouse strains tested (Figure 12). This may be due
to difference in ALG treatment schedule or properties of
the antibody preparation itself. However, it is appreciated
that antigen doses in excess of 3 x 109 SRBC might overcome
the immunosuppressive effects of the ALG treatment. Indeed
there is a suggestion that the degree of suppression in
animals given the highest antigen dose (3 x 109 SRBC) is
somewhat lower than that achieved in animals given the lower
dose (3 x lO'' SRBC| Figure 12 )•
Several authors have reported results indicating the
inability of ALG to suppress the secondary immune response
of either rats or mice to sheep erythrocytes (James and
Anderson, 19671 Lance, 1968a? Monaco, Wood and Russell,
1965) and to BSA (James and Jubb, 1967? James and





















1972)* In contrast to those reports* the ALG used in
this series of experiments was able to suppress the
secondary immune response to SRBC in all the mouse strains
tested (Figure 13)* However these findings are in general
agreement with the earlier observations made by Barth and
Southworth (1968) with SRBC, those of Marshall and Knight
(1969) with BSA, and those of Lance (1970b) with Salmonella
typhi *H* antigen. These contrasting results could perhaps
be explained on the basis of species variations, differences
in the properties of ALG preparations used and the experi¬
mental models employed.
It is interesting to note in Figure 13 that the
secondary response in A/HeJ mice was least susceptible
to supi3res8ion by ALG and that this was most evident with
respect to the IgG response. It should also be recalled
that it was in A/HeJ mice that ALG treatment potentiated
the secondary IfiCG0a response against sheep erythrocytes
(Table 19) and failed to suppress the primary IgG response
to this antigen (Table 7)« This may also form the basis
for explaining the inability of ALG to suppress the secondary
response to alum BSA in the hands of various people (James
and Jubb, 1967; Lance, 1968a, 1970a,b). On these occasions
the antigen may have been stimulating the preferential
production of antibody in certain immunoglobulin subclasses
which are not readily suppressed (or indeed may be enhanced)
by ALG treatment. In this connection, the recent findings
-98a-
FIGURE 13
EFFECT OFALG ON THE SECONDARY IMMUNE RESPONSE IN




















































of Torrigiani (1972a) which indicated that the antibody
response to alum-precipitated human serum albumin was
mainly localized in IgG^ and IgG0a subclasses and those
of Anderson and her colleagues suggesting the augmentation
of anti-SRBC response in these very XgG subclasses by aLG
treatment may be of significance (Anderson, Dresser,
Iverson, Lance, Vortis and Zebra, 1972). Also, it is
possible that the utilization of different adjuvants
might significantly Influence the distribution of antibodies
among the various immunoglobulin classes and subclasses.
In this connection it is interesting to note that adjuvants
can preferentially stimulate the production of antibodies
in specific immunoglobulin classes and subclasses in both
the mouse (Coe, 1966i Warner, Val and Ovary, 1968), and
the guinea pig (Benacerraf, Ovary, Eloch and Franklin,
19031 White, Jenkins and Wilkinson, 1963)*
In order to investigate the effect of ALG on classes
or subclasses of antibody produced following antigen
stimulation, the secondary immune response of different
mouse strains to SRBC has been studied. Due to the
limited amount of anti-immunoglobulin sera available,
these studies were performed in only four mouse strains.
Xhe results of these studies clearly indicate that the
ALG used in these studies (ALG Id) successfully suppressed
the XgM and XgG^ responses in all four mouse strains tested















































































in all mouse strains except A/HeJ mice, whereas the
and IgA responses were not significantly suppressed in
Balb/c mice. The latter seemed to be due to large
variations in the responsiveness of individual Balb/c
mice in these immunoglobulin classes (3-265 I®Cr2a and
1-258 IgG PFC per 10° cells). However, in DBA/1 and
C^H mice the ALQ treatment suppressed antibody formation
in all immunoglobulin classes and subclasses.
Several explanations can be offered for the differences
between the results described here and those reported by
Anderson and others (Anderson, Dresser, Iverson, Lance,
Vortis and Zebra, 1972). Firstly, the results reported
by Anderson and others were from studies on a late primary
immune response. It is very likely that IgQ^ and IgG2a
responses were the first to recover in the ALG-treated
mice. Furthermore, since the ALG treatment had caused
a suppression of anti-SRBC response in other immunoglobulin
clas.es, seme of which nay have regulatory offsets on Xg01
end Ig02a antibodies, these responses nay have over,hot
the responses in control mice not treated with ALG. Such
a control of immune responses by antibodies have been
demonstrated by various workers and these observations
have been reviewed by Uhr and Holler (1968). Other
factors which may account for the discrepancy include
the differences in the properties of ALG preparations used
and the strains of mice studied.
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The data on the circulating serum agglutinin and
haemolysin responses in general confirmed those obtained
by PFC assays. The AUG treatment of mice resulted in
the suppression of both the haemagglutinin and haemolysin
responses. In order to measure the 7S haemagglutinin and
haemolysin responses in these experiments, the sera were
treated with 2-mercaptoethanol. It has been shown that
reduction of sera with 2-mercaptoethanol destroys the
ability of 19S and lis antibodies to cause agglutination
and haemolysis (Pudenberg and Kunkel, 1957) Hockey and
Kunkel, 19o2). It is nevertheless appreciated that some
7S antibodies may be sensitive to 2-mercaptoethanol treat¬
ment (Adler, 1965b).
The results of agglutinin and haemolysin titres in
2-mercaptoethanol treated sera (Tables 13 and 1*0
indicated that increasing the dose of antigen (3 x 10/ -
9 \
3 x 10 SRBC) resulted in an increased amount of 2-mercapto-
ethanol-resistant (igG) antibody. A relative increase in the
amount of IgG antibody with an increasing dose of SRBC
has previously been observed (Wortis, Dresser and Anderson,
1969) Sinclair, 1967). None of the animals treated with
ALG showed detectable amounts of 2-mercaptoethanol-reaiatant
haemagglutinating or haemolytic antibody on the fourth or
fifth days after the primary challenge (Tables 8-11 and
13-1*0 •
There was a much greater proportion of 2-mercaptoethanol-
-102-
resistant antibody following the secondary challenge than
there was following the primary one. An increase in the
production of IgG antibody in the secondary immune response
has been previously reported (Adler, 1965a» Sinclair, 1967t
Sell, Park and Nordin, 1970). Nevertheless, AUG treatment
caused a significant suppression of both total and 2-mercapto-
ethanol-resistant antibody responses (Figures 15 and 16).
It should be noted that haemolysin responses were more
readily suppressed than haemagglutinin responses. Also,
ALG treatment suppressed the 2-mercaptoethanol-resistant
antibody titree more readily than it did the 2-mercapto-
ethanol sensitive ones. It is also apparent that the
suppression of secondary circulating antibody responses
was not as effective as the suppression of primary ones.
In addition, the effectiveness of ALG to suppress the
secondary PFC responses was more apparent than the suppression
of secondary circulating antibody responses. This is in
agreement with the findings of Barth and Southvorth (1968)
who showed that ALG treatment significantly suppressed
both direct and indirect secondary PFC responses, but
failed to suppress the secondary agglutinin responses.
Experiments on the recovery of the immune response
to SRBC in mice treated with ALG indicate that the primary
immune response of imraunosuppressed mice did not recover
for a very long time. Indeed, it is appreciated that







































































































































recovery from a single regimen of ALG treatment. However,
when these mice were rechallonged, they gave a secondary
response no different from that of control mice (Figures 9
and 10). These observations are strictly in agreement
with those recorded by other workers (Leuchars, Wallis
and Davles, 1968; fiaura, Liebermann and Frenkel, 1969).
The normal secondary response in ALG-treated animals
clearly indicates that ALG treatment prior to the primary
challenge, although it suppressed the primary antibody
response, did not prevent the eventual sensitization of
the recipient mice. This may imply that the ALG treatment
suppressed the primary response not entirely by the elimination
of SRBC antigen sensitive cells (of thymus or marrow origin),
but it may also have caused the suppression by interfering
with a step in the immune response following antigen
recognition. The other alternative explanation for the
proceeding findings may be that small amounts of antigen
administered for the primary sensitization persisted for
a long time and as the lymphoid cells (probably *T* cells)
recovered from the effects of ALG treatment, they became
sensitized to the antigen. The latter hypothesis would
be consistent with the earlier observations showing the
inability of adult thymectomlzed animals to give a normal
secondary response when treated with ALG prior to the
primary sensitization with SRBC (Leuchars, Wallis and
Davies, 1968). In this context it is interesting to
-10k-
note that small amounts of SRBC antigen have been shown
to persist in immunogenic form for up to Ik days after
its administration (Britton, Vepsic and Moller, 1968).
It should also be borne in mind that relatively small
quantities of antigen are required to sensitise ,T*
lymphocytes (Chillerf Habicht and Weigle, 1971? Playfair
and Purves, 1971? Playfair, 1972).
The suppression of anti-SRBC response by the ALG
preparation Id might be due to its effect on two major
populations of lymphoid cells. It may have inactivated
the thymus-derived lymphocytes which are essential for
the induction of anti-SRBC response or have impaired the
function of the precursors of antibody producing *B' cells.
Xt is appreciated that in addition to these two targets,
ALG may be interfering with the functions of other cells
involved in the immune response, e.g. macrophages. The
indispensable nature of macrophages in the induction of
immune response to different antigens is now well established
(reviewed in the Introduction).
Antisera produced against macrophages have been shown
to suppress the immune response to SRBC (Argyris and Plotkin,
1969* 1970) and other antigens (isa, 1971? Schick, 1972).
Xt has also been reported that antisera produced against
lymphoid cells may strongly cross react with macrophages
and related cells (Ruber, Michlaayr and Fudenberg, 1969?
Sheagren, Barth, Bdelin and Malmgren, 1969? Woodruff,
-105
Anderson and Abaza, 1966; DiLuzio and Piaano, 1970;
Marsmart, van der Hart and van Loghem, 1970). Furthermore,
In vivo studies have shown that anti-lymphocytic antibodies
may severely impair the clearance of" zaacramolecular
substances from the blood stream (Boak, 1968; Sheagren,
Barth, Edelin and Malmgren, 1969? Grogan, 1969? Barth,
Hunter, Southworth and Rubeon, 1969). In addition a
direct deficiency of macrophage function has been demonstrated
following ALG treatment in rats where the suppression of
anti-SRBC response could be reversed by the reconstruction
of the ALG-treated animals with macrophages (Patterson,
Pisano and DiLuzio, 1970).
In order to determine if the ALG preparation Id could
act on the ,B* cell population in addition to •T* cells
the studies on its effect on the immune response to SSS-III
were undertaken. As previously stated, it has been shown
that thymus plays no role in the initiation of the immune
response against this antigen (Humphrey, Parrott and
DeSousa, 1964? Davies, Carter, Leuchars, Wallis and
Dietrich, 1970; Howard, Christie, Courtenay, Leuchars
and D&vies, 1971).
The results of these experiments conclusively
demonstrate that ALG Id was able to effectively suppress
the immune response to SSS-III in a variety of mouse
.strains (Tables 24-26; Figure 17) • These results


















































































this antigen, and those of Allen, Freodraan and Hills (l969)
with E. coli lipopolysaccharide (LPS); the latter being
another thymus independent antigen (Anderson and Blotagren,
1971) Moller and Michael, 1971)* However, they are
completely in contrast with the findings initially reported
*
by Baker and his colleagues with SSS-XII antigen in Balb/c
mice (Baker, Stashak and Amsbaugh, 1970; Baker, Stashak,
Amsbaugh, Prescott and Barth, 1970; Barth, Baker, Stashak
and Amsbaugh, 1971)» and those of Kerbel and Eidinger (1971)
with polyvinyl pyrrolidone, and Veit and Michael (1972) with
E. coli LPS.
It is also apparent from the results recorded in
Figure 17 that the immunosuppressive capacity of ALG is
not completely overcome by increasing the quantity of the
antigen administered (at least in the dose range used in
these experiments). Nevertheless the degree of suppression
achieved by ALG seemed to be less marked in mice immunized
with the higher antigen dose (5 Hg.). The inability of
the higher antigen dose to completely overcome the immuno¬
suppressive capacity of ALG is once again in contrast
with the findings with other antigens (Lance, 1970a,b;
Argyris and Plotkin, 1970).
There are a number of possible explanations for the
difference between these results and those of Baker and
his colleagues. While at one time it was thought that
one contributing factor might have been the mouse strains
-107-
used (James and Milne, 1972), the present results rule out
this possibility, for ALG Id suppressed the anti-SSS-III
response in Balb/c mice. It should be recalled that the
potentiation of antl-SSS-III response was observed in this
very mouse strain (Baker, Barth, Stashak and Amsbaugh,
1970j Baker, Stashak, Amsbaugh, Prescott and Barth, 1970;
Barth, Baker, Stashak and Amsbaugh, 1971). Furthermore,
it is unlikely that they are due to the differences in the
procedures for measuring the immune response, since the
specificity of the assay procedure employed in these studies
was established by the inhibition of anti-SSS-XII plaques
with purified soluble antigen (Figure 8), This was also
true of the procedures used by Baker and his colleagues
(Baker, Prescott, Stashak and Amsbaugh, 1971). Another
two possible factors will be discussed later. These are
basic differences in the ALG treatment schedule used and
in the intrinsic properties of the ALG preparations.
Due to the difference between the present results
and those of Baker and his colleagues it seemed imperative
to ascertain if the ability of preparation Id to suppress
anti-SSS-III response was unique to this product or was
a property shared by other antisera. In order to determine
this, a number of other ALG preparations raised in other
horses were tested. It could also be argued that ALG Id
was so effective in suppressing anti-SSS-III response
because it was a mult!pulse serum and hence it had lost
-lOS-
the ability to discriminate between 'T* and *B' cells.
It should be stressed that previous observations have
indicated a loss of specificity in anti-lymphocytic
sera as a result of hyperimmunization of the production
animal (Sutthivan, Shorter, Hallenbeck and Elveback, 19691
Jooste, Lance, Levey, Medawar, Kuskiewicz, Sharman and
Taub, 1968). Consequently ALG preparations were isolated
from antisera obtained from a single horse at various times
throughout its immunization course and their effects on the
immune response to SSS-XII were tested.
It is readily apparent from the results that the ability
of anti-lymphocytic antibody to suppress the thymus independent
response against SSS-XII is not a property singly unique to
the ALG Id preparation widely used in these studies.
Nevertheless, it is perhaps true to say that this product
appears relatively more efficient at suppressing the immune
response to SSS-III than the other ALG preparations tested
(Figure 18). It also appears from the results that certain
ALG preparations (e.g. preparation 4 in Figure 18) may cause
alight augmentation in the total splenic PFC response to
SSS-III. However, on no occasion did this potentiation
approach that previously observed by other workers with
this antigen (Baker, Earth, Stashak and Amsbaugh, 1970}
Baker, Stashak, Amsbaugh, Prescott and Barth, 1970}
Barth, Baker, Stashak and Amsbaugh, 1971)• It should























the results of Baker and his colleagues with a number of
thymus independent antigens (Allen, Friedman and Mills,
19691 James and Milne, 1972} Veit and Michael, 1972),
Furthermore, if the potentiation of immune response to
thymus independent antigens by ALO treatment were due to
the elimination of a suppressor •T* cell population, as
has been postulated by Baker and his colleagues (Baker,
Stashak, Amsb&ugh, Prescott and Barth, 1970), a similar
effect should be produced by the elimination of *T' cells
by neonatal thymectomy or by adult thymectomy and radiation.
However, so far no such effect has been observed following
these treatments (Howard, Christie, Courtenay, Leuchars
and Davies, 1971) Andersson and Blomgren, 1971} Veit
and Michael, 1972).
It can also be seen from the results that whenever
the total PFC response was potentiated by ALG treatment,
this could at least partly be attributed to the accompanying
splenic hyperplasia. For, the PFC per 10° nucleated spleen
cells never significantly exceeded that observed In the
normal IgG-treated controls. As previously emphasized an
increase in plasma cell and other cell populations has
been observed by previous investigators following ALG
treatment (Taub and Lance, 1968; Denman and Frenkel, 1963b;
Marshall and Knight, 1969; Simpson and Nehlsen, 1970)
Rodrlguez-Paradisi, Thierfelder, Gotze, Eulitz and Beil,
1971).
-110-
The ability of certain ALG preparations to suppress
the immune response to SSS-IIX is undoubtedly influenced
by the strain of animals in which they are tested (see
Figure 18) although this difference was not noticeable
with ALG Id. In this respect it is interesting to note
that the products tested were more efficient in Balb/c
mice, the strain in which previous investigators found a
significant enhancement of anti-SSS-III response following
treatment with ALG (Baker, Barth, Stashak and Amsbaugh,
1970} Baker, Stashak, Amsbaugh., Frescott and Barth, 1970;
Barth, Baker, Stashak and Amsbaugh, 1971)* This further
excludes the possibility that the differences in the results
of the two studies could be due to the mouse strain used.
It should be re-emphasized that similar strain specific
effects following treatment with ALG have been observed in
rats (James, Pullar and James, 1969) and mice (James and
Milne, 1972). It is also interesting to note that the
relative sensitivity of Balb/c mice to the immunosuppressive
effects of ALG could not be attributed to the origin of
thymocytes used for immunization as none of the preparations
were raised by immunization with thymocytes from this mouse
strain.
One of the factors most likely to explain the differences
between the present results and those of Baker and his
colleagues was the schedule of ALG treatment used. The
results so far discussed were obtained from animals treated
111-
with AJUG on days -4 and -2 prior to antigen administration.
Xn contrast in the bulk of the studies by Baker and his
colleagues the ALG was administered simultaneously with
(or just before) the antigen (Barth, Baker* Stashak and
Amsbaugh, 1971). In order to test this possibility the
two schedules of ALG treatment were compared in Dalb/c
mice.
The results of these studies clearly indicate that
the immune response to SSS-III is more readily suppressed
if the ALG treatment is commenced some days prior to anti¬
genic challenge (Figure 19). If the ALG treatment was
delayed until just prior to antigenic challenge then It
may be less effective (as in the case of preparation le)
or without a significant effect (see preparations 2-4).
A similar situation has been noted with respect to the
immune response of rats to alum BSA (James, 19 >7) and
mice to SRBC (Berenbaum, 19671 Baroni, Kimball, Ward and
Wagar, 1969). While this might explain in port the
differences between the results recorded here and those
previously reported by Baker and his colleagues (Baker,
Barth, Stashak and Amsbaugh, 1970j Baker, Stashak,
Amsbaugh, Preecott and Barth, 1970? Barth, Baker,
Stashak and Amsbaugh, 1971), it could not be the sole
explanation, for, in no instance was there the marked
potentiation observed by Baker and his colleagues.
As stated earlier, one possible explanation of these
-111a-
FXGURE 19
EFFECT OF ALTERNATIVE SCHEDULE OF ALG TREATMENT ON
















discrepancies la unique differences in the various ALG
preparations used. In order to determine if the effective¬
ness of the ALG was due to the multiple immunization
schedule used in its production, the effect of ALG
preparations isolated from sera obtained &t various
stages of immunization of the ALG donor were tested.
It is obvious from the results that the ability of
ALG Id to suppress anti-SSS-UX response could not be
merely due to hyporimmunization of the horse, for, the
ALG preparation obtained after only two Injections of
thymocytes (lb) was already effective at suppressing
anti-SSS-III response (see Figure 18). The ALG preparation
la which did not suppress the immune response to SSS-III
also failed to suppress the anti-SRBC response (Figure 21).
In addition product Id was more effective than products
2-k which were produced by extremely chronic and/or prolonged
immunization schedule (see Table 2). Furthermore, the
inactive product described by previous authors (Baker,
Barth, Stasliak and Amsbaugh, 1970} Baker, St&shak, Amsbaugh,
Prescott and Barth, 1970} Barth, Baker, Staehak and Ainsbaugh,
1971) vas produced by a fairly chronic immunization schedule
(Barth, 1969)- However, it is obvious that the immuno¬
suppressive potency of ALG produced in a single horse did
increase with repeated immunization (Figure 18). It
should be stressed that none of the products employed in
these studies were toxic in vivo after absorption with
113-
mouse erythrocytes.
In conclusion, the most likely explanation of the
differences between these results and those of other
workers (Baker, Barth, Stashak and Amsbaugh, 1970;
Baker, Stashak, Atnsbaugh, Prescott and Barth, 1970;
Barth, Baker, Stashak and Amsbaugh, 1971I Korbel and
dinger, 1971) are differences in the ALG treatment
schedule and the basic differences in the properties of
the ALG preparations themselves. The latter differences
may be determined by the nature of the antigen used in
the production of anti-lymphocyte sera, the immunization
schedule adopted, the mode of antigen administration (i.e.
its incorporation into adjuvants) and the immune response
of individual production animals. The fact that the
antisera used in this study were produced against normal
•*
thymocytes in horses and the antiserum used by Baker and
his colleagues was raised against rcethylcholenthrone-
Induced lymphoma colls in burro (Barth, 1969) may be
significant. It is also interesting to note that anti-
sera used in other studies where no suppression of thymus
independent responses were noted were produced without
adjuvant (Kerbel and Eidinger, 1971; Veit and Michael,
1972). However, it cannot explain the differences between
the results reported here and those of Baker and his
colleagues, for, they also used adjuvant in the production
of their antiserum.
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While most of the ALG preparations tested significantly
suppressed the PFC response to SSS-III, their effect on
circulating formation was less marked (Figure 20). This
may be due to qualitative differences in the antibodies
measured by these two techniques, e.g. immunoglobulin
classes, binding affinities, etc. It should be pointed
out that such differences have been recorded by certain
investigators (Kearney and Ilalllday, 1970a,b).
Throughout these studies it was assumed that the inrnmne
response to type-Ill pneumococcal polysaccharide is completely
thymus independent (B-cell process), at least as far as
CBA mice are concerned and there exists a considerable
amount of evidence to support this assumption (Daviea,
Carter, Leuchars, Wallis and Deitrich, 19?0» Howard,
Christie, Courtenay, Leuchars and Davies, 1971)• Accepting
that a similar situation is operative in other strains of
mice, and there is data to suggest that this is so (Humphrey,
Parrott and East, 1964; Manning, Reed and Jutila, 1972),
one would conclude that ALG suppresses the immune response
to this antigen by inactivating or interfering with the
function of the thymus independent (b) lymphoid coll
population. However, there is a body of evidence that
anti-lymphocyte sera may react with lymphoid cells of
extra-thyraie origin. For example using colony forming
unit assays several authors have showed that ALG could























































(DeMeester and Anderson, 1968; DeMeester, Anderson and
Shaffer, 1968; Nouza, ]iaskovcova and Nemec, 1971) •
In addition Jeejeebhoy and Singla (1972b) showed that
the inability of ALG-treated rats to respond to SRBC
was in part due to temporary damage or inactivation of
bone marrow cells. Also, Andersaon and her colleagues
(1970) demonstrated that their ALG preparation could
suppress anti-hapten response in an adoptive situation
where the donors of the producer lymphoid cells were
treated with ALG. It should be noted that the production
of anti-hapten antibody is carried out by ,BI cells
(Mitchison, 1971a). Furthermore, the recent observations
of Janossy and Greaves (1972) who demonstrated that anti-
thymocyte antibody preparations could interfere in vitro
with either •T* cell or 'B* cell responses or both provide
additional support to the view that ALG can react with
non-thymic lymphoid cells. Finally, there is abundant
evidence that anti-lymphocyte sera may interfere with the
function of macrophages (see earlier), a cell population
which might be involved in the immune response against
SSS-III (Aaskov and Ha11iday, 1971)• It is possible
that the effectiveness of certain ALG preparations (like
Id in these studies) in suppressing both thymus dependent
and thymus independent humoral immune responses may be
due to their ability to interfere with the function of
*T* cells, *B' cells and macrophages.
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fhe results obtained from the preliminary cell
reconstltution experiments suggest that the Immunological
injury caused by the ALG treatment may be repaired, at
least partially, by either ,BI cells (Table 37t group D)
or •T* cells (Table 37» group C), The bearing of these
findings on the thymus dependence of the SSS-III response
is not clear at present. It should, however, be noted
that recent evidence suggests that thymus cells may play
a role in the immune roeponae to SSS-III, as the response
to this antigen in thymus-deprived mice has been shown to
be less sustained than in reconstituted mice (Howard,
Christie, Courtenay, Leuchars and Davies, 1971). In the
experiments reported here, it is possible that reconstitution
of anti-SSS-III response by thymocytes was achieved simply
because these cells accelerated the regeneration or pro¬
liferation of ,BI cells in lymphocyte depleted mice. It
should however be stressed that before any definite
conclusions are drawn the reproducibility of these
findings must be ascertained.
In order to establish that ALG preparations la-lc
and 2-4 were comparable with the Id preparation, their
effect on the immune response against thymus dependent
antigens, BSA and SRBC was examined. It is apparent that
ALG preparations 2-4 also significantly suppressed these
responses, although the degree of suppression varied from
one preparation to the other (Figures 21 and 22). It Is
-117-
also interesting to note that their ability to suppress
thymus independent responses was not related to their
effectiveness on thymus dependent responses (compare
effect of ALO 2-4 in CIJA mice in Figure 18 with that
in Figures 21 and 22).
It is also apparent that ALG la effectively suppressed
the immune response to DSA but did not suppress the IgM
responses against SRBC and SSS-III. Furthermore all the
ALG preparations were much more effective at suppressing
IgG responses to SRBC than IgM responses (la-Id and 2-4;
Figure 21). It should also be stressed that ALG la
suppressed the IgG anti-SRBC response but failed to
significantly suppress the anti-SRBC IgM response (Figure 21).
It should be pointed out that the anti-BSA response measured
at three weeks after immunization would be expected to be
mostly in the IgG immunoglobulin class. It may he relevant
to mention here that Tarrigiani {1972atb) found that immune
response to alum-precipitated human serum albumin at 3 weeks
after immunization was mostly in the IgG class. Thus it
appears that the ALG is generally more effective in sup¬
pressing immune responses of IgG immunoglobulin class.
This Is also supported by the data from the 2-mercapto-
othanol sensitivity of sera obtained from control and ALG-
treated animals (Figures 13 and 16).
The production of certain IgG subclasses is believed
to be dependent on the participation of the thymus. This
-117a-
FIGURE 21
ABILITY OF DIFFERENT ALG PREPARATIONS TO SUPPRESS
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FIGURE 22
ABILITY OF DIFFERENT ALG PREPARATIONS TO SUPPRESS
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view Is based upon the relative deficiency of IgG in mice
displaying thymic aplasia (Luzzati and Jacobson, 19721
Pritchard, Itiddavay and Micklem, 1973) end in humans
vith thymic deficiency diseases (Peterson and Good, 1963;
Siegal, Pernio and Kunkel, 1971)* Similarly, mice
experimentally made thymus-deficient show a decrease in
the level of antibody response in certain IgG subclasses
(Taylor and Wortis, 1963; Torrigiani, 1972b). It should
also be mentioned that the most of the immune responses
which are produced in the absence of thymic influence are
mainly of the IgM type (Britton and Holler, 1968; Taylor
and Wortls, 1968; Aird, 1971; Howard, Christie, Court©nay,
Leuchars and D&vies, 1971* Pritchard, Riddavay and Micklem,
1973)* On this basis it will be reasonable to postulate
that ALG can generally suppress thymus dependent responses
more effectively and with greater ease than the thymus
independent ones.
While the results of the studies reported hero indicate
that antisera capable of suppressing *B' cell responses may
be produced by modest immunization schedules, it might be
possible to produce antisera capable of specifically
inhibiting •T* cell responses by the 2-pulae immunising
schedule of Levey and Medawar (1966a) which does not employ
adjuvants. It should again be recalled that antisera
used by authors who were not able to suppress the iKsaune
responses against thymus independent antigens were raised
-1X9
by this procedure (Kerbel and Eidinger, 1971I Veit and
Michael, 1972). However, an overall consideration of
the data presented here clearly indicates that the use
of anti-lymphocytic sera as selective depletors in
immunological systems (a practice pursued in some laboratories)
may on occasions give rise to erroneous conclusions. It
is evident that before such antisera can be used for this
purpose, their specificity must be carefully established.
Their effect on the immune responses against thymus
independent antigens may be one of the in vivo methods
of some value in determining their specificity.
CONCLUDING REMARKS
-120
Prom the data presented in this thesis (see Tables 39
and **0), it can be concluded that most ALG preparations
are capable of suppressing humoral immune responses against
the thymus dependent antigens SRBC and BSA. In addition,
a number of ALG preparations can also suppress the immune
responses against thymus independent antigens (e.g. SSS-IIl).
Thus, anti-lymphocytic sera may exert their immunosuppressive
effects by interfering with the function of both *T* and
•B* cells. However, the evidence presented does suggest
that thymus dependent immune responses are more susceptible
than the thymus independent ones. Furthermore, the action
of anti-lymphocytic sera through macrophages remains a
likely possibility.
It is also apparent that the immunosuppressive properties
of ALG may be influenced to some extent by the dose of antigen
administered and the strain of animals in which they are
tested. In addition, the ability of ALG at suppressing
humoral immune responses may largely depend upon the time
of its administration in relation to the antigenic challenge.
Finally, the results indicate that individual ALG
preparations may differ greatly from each other in their
immunosuppressive properties even though they are raised
in the same species by almost identical procedures.
Nevertheless, there is some evidence that hyperimmunization
may lead on occasions to more potent anti-lymphocytic sera













































































































































TABLE frO - A SUMMARY OF THE ABILITY OF VARIOUS ALG




ALG Pre p IfiM IgG -h | -2d 0d'°
la Yese No Yes No -
lb Yes Yes Yes Yes -
lc Yes Yes Yes Yes -
Id Yes Yes Yes Yes Yes
2 Yes Yes Yes Yes) No
3 Yes Yes Yes
)f
Yes) No
k Yes Yes Yes Yes« No
(a) All experiments except with SSS-XII were carried
out in CBA mice only. SSS-IXX was tested in
both CBA and Balb/c mice.
(b) See Table 2 for details.
(c) Indicates that the suppression achieved was
statistically significant (PO.05).
(d) Time in days of ALG administration in relation
to antigen given on day O: in case of BSA and
SRBC ALG was always administered on day -4 and
-2.
(e) Experiments carried out in Balb/o mice.
(f) Suppression was statistically significant only
in Balb/c mice but not in CBA mice.
(g) Significant suppression in Balb/c mice whereas
a significant potentiation in CBA mice.
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It may b© relevant to list here certain aspects of
the immunosuppressive properties of ALG which should be
investigated further. Por instance, it would be interest¬
ing to test the immunosuppressive properties of several
antl-lymphocytic sera produced in different species by
different immunization methods (e.g. different immunization
schedules; with and without the use of adjuvants, etc.).
As the studies reported in this thesis were not designed to
explain the mode of action of AJjG in humoral immune responses
it would be interesting to perform further experiments and
to determine the target of ALG action. In this connection
experiments should be undertaken to confirm if thymus cells
can really restore the capacity of ALG-treated animals to
respond to SSS-III.
In view of the recent findings of Jeejeebhoy and
Singla (1972a) it would be interesting to ascertain if
ALG treatment results in the release of soluble factors
which may influence Immunological processes. It has been
shown in vitro the the binding of ALG to lymphocytes may
result in the formation of soluble factors which interfere
with the normal behaviour of macrophages (Caspary, Hughes
and Field, 1970). This hypothesis may provide additional
explanation for the lack of correlation between lymphopenia
and immunosuppression following ALG treatment.
The effect of ALG on the production of antibody in
different immunoglobulin classes and subclasses undoubtedly
-122-
requires further investigation. This is especially so
in the case of primary immune responses and should be
investigated with a variety of antigens and adjuvants.
Furthermore, studies into the adjuvant effects of the ALG
treatment should be undertaken. While, it is established
that most ALG preparations cause immunosuppression when
given in large dose, they could possibly potentiate immune
responses when administered at suboptimal doses.
The use of ALG as a carrier for antigens should also
be explored. It is conceivable that the accessibility
of the antigen (local concentration) around the lymphoid
cells may be the limiting factor in determining the immuno—
genicity of certain antigens and this accessibility could
be facilitated by the linkage of the antigen to a non-
cytolytic form of ALG ( for example, IgG F(ab)2 ).
As previously stressed these studies were not designed
to determine the mode of action of anti-lymphocytic sera.
However, it may be relevant to comment here on the possible
mechanisms by which these reagents may cause the suppression
of cellular and humoral immune responses.
The most likely targets of action of anti-lyraphocytic
sera are the cells of the lymphoreticular system, the
recirculating long-lived antigen sensitive cells of thymic
origin being the most popular candidate (Turk and Willoughby,
19671 Taub and Lance, 1968; Denman, Dexunan and Embllng,
1968; Everett, Schwarz, Tyler and Perkins, 1970). The
-123-
temporary inactivation or destruction of this cell population
by anti-lymphocytic sera is believed to account for the
suppression by ALG of all cell-mediated immune responses
(Medawar, 1969» TurBi, Greaves, Torrigiani, Playfair
and Roitt, 1969f Lance, 1970a) as well as most humoral
immune responses (Moller and Zukovski, 1968; Martin and
Miller, 1968; Leuchare, ¥allis and Davies, 1968).
However, there is now sufficient evidence to indicate that
anti-lymphocytic sera may interfere with the thymus in¬
dependent (B) lymphocyte population (DeHeester, Anderson
and Shaffer, 1968) which may ultimately result in the
suppression of humoral Immune responses (jeejeebhoy, 1970).
The suppression of certain humoral immune responses which
are independent of thymic cell participation by anti-
lymphocytic sera (Shellam, 1969; Allan, Freeman and Mills,
1970; James and Milne, 1971) further support this view.
In addition, anti-lymphocytic sera have also been shown to
act on and interfere with the function of macrophages.
The evidence for the effect of these reagents on and the
role of macrophages in immune reactions has already been
reviewed in the earlier parts of this thesis.
In summary, anti-lymphocytic sera may exert their
effect upon immune responses by interacting with several
components of the lymphoreticular system. While in
general it would be true to say that these reagents act
preferentially on lymphocytes of the recirculating pool;
•12k"
as Kiteillson (1970) said, "It is simply tdo soldiers who
stick their heads above the parapet who got shot."
The exact mechanism of cellular elimination may include
complement mediated cytotoxic destruction and phagocytosis
of opsonized cells. Alternative but less likely mechanisms
of cellular inactivation include blindfolding, enhancement,
sterile inactivation, antigen competition, etc. Xn
addition to cellular targets, anti-lymphocytic sera have
also been proposed to act via non-cellular factors such
as thymic humoral factors (Nagaya, 1970), lymph node
permeability factor (lurk and Willoughby, 19o9), immuno¬
globulin receptors (Huber, Micblmayr and Fudenberg, 19^9{
James, Pullar, James, Wood, Epps and Kahr, 1970), and
complement (villoughby, 19j8).
It should be stressed here that although the results
recorded in this thesis do not specifically support any
of the views on the mode of action of anti-lymphocytic sera
(see James, 1973t), they do not contrast with any of the
theories eo far advanced. Vfcile the results discussed
earlier provide information on how ALG interferes with the
function of cells of the lymphoreticular system, they
favour the view that this reagent may on occasions interfere
with the function of both *T* and ceils and possibly
macrophages. The implications of these cells in the








Make up to one litre with distilled vater
Solution B
NallgPO^ 31.2 gin
Make up to one litre with distilled vater
O.OlMi pH 7.5 buffer
168 ml solution A plus 32 ml solution B| make
up to k litres with distilled water
0.01M? pH 8.0 buffer
ISO ml solution A plus 20 ml solution 0} make
up to 4 litres with distilled water.
FgOSPHATB BUFFERED SALINE (pH 7.2)
400 ml 1.5M (87.675 gm per litre) NaCl
900 ml phosphate buffer solution A
300 ml phosphate buffer solution B




1) NaCl 80 em
K CI 4 gm
Mg&0k (7 HgO) 1 ts*
MgCl (6 HgO) 1 gm
Dissolve in 4O0 ml distilled water
2) CaCl^ (anhydrous) 1.4 gui
Dissolved in 50 ml distilled water
Add solutions 2 and 1 slowly- with constant miring and
adjust the volume to 500 ml with distilled water.
Sterilize by outoclaving at 101b. p.s.i. for 10 minutes.
Stock Solution B
Na2HP0^ (12 H20) 1.52 gn
KH2P0^ 0.60 gm
Glucose 10.00 get
Dissolve in distilled water and make up to 500 ml
Sterilize by autoclaving at 101b. p.s.i. for 10 minutes
Stock Solution C
NaHCO^ 1.4 gm in 100 ml distilled water. Sterilized by
ultrafiltration. Saturate with C02 and store in 5 ml. aliquots.
To obtain a working Hank's solution, mix 5 ml of solution
A, 5 ml of solution B and 2.5 ml of solution C and make up
to 100 ml with sterile distilled water.
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TRYPAN BLUE
1 gm trypan blue in 100 ml distilled water. Filter
and store sterile.
To make a working solution add 1 ml stock solution
to 14 ml of Hank's solution.
VERONAL BUFFERED SALINE
NaCl 85.00 gm
MgClg (6 HgO) 16.8 gm
C«CX2 (anliytlroue) 0.28 gn>
5:5-diethyl barbituric acid 5.575 gm
Na-barbiturate 2.0 gm
Dissolve in distilled water and make up to 200 ml.
Dilute 1 in 5 in distilled water before use.
BORATE DUFFER (pH 8.3-8.5)
Boric acid 6.184 gm
Sodium tetraborate 9*536 gm
Sodium chloride 4.384 gm
Dissolve in distilled water and make up to 1 litre.
APPENDIX II
VARIATIONS IN THE IMMUNE
RESPONSE OP DIFFERENT MOUSE STRAINS
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In the course of studies on the effect of ALG on the
humoral immune responses of different mouse strains to
SRBC and SSS-IXI it appeared from the immune response of
control animals that different strains of mice varied
significantly in their ability to respond to these antigens.
Furthermore, earlier studies carried out in this laboratory
on the effect of ALG on the immune response to BSA in
different mouse strains indicated similar interstraln
variations (James and Milne, 1972),
For a number of reasons, however, it was not possible
to draw firm conclusions on these lnterstrain differences*
Firstly, not all the experiments with one particular
antigen were carried out simultaneously and therefore it
was not possible to account for the variability from one
experiment to the other. Xn addition, the prior treatment
with normal horse IgG could have modified the response to
test antigens and might have varied from strain to strain.
Xn this connection it is interesting to note that Berth
and his colleagues reported a suppression in the immune
response of Balb/c mice against SRBC by prior treatment,
with normal rabbit IgG (Barth and Southvorth, 1968;
Barth, Hunter and Southworth, 19«9l Barth and Carroll,
1970)• The same group of workers also reported the
suppression of anti-SSS-III response of Balb/c mice by
normal burro serum treatment (Baker, Barth, St&shak and
Amsbaugh, 1970; Barth, Baker, St&shak and Arasbaugh, 1971).
-129-
A similar suppression of anti-SRBC response by normal rabbit
IgG has been reported in both rats (Baum, Lieberman and
Frenkel, 1969)» and mice (Baroni, Kimbal, Ward and Wagar,
1969)* In contrast, Anderson and her colleagues observed
an enhancement of anti-SRBC response by normal rabbit
globulin (Anderson, Dresser, Iverson, Lance, Wortis and
Zebra, 1972). Similarly, moderate to severe enhancement
of antibody responses by the normal rabbit globulin treatment
have been recorded by various other workers (Marshall and
Knight, 1969t Baroni, Kimbal, Ward and Wagar, 19691
Jeejeebhoy and Singla, 1972a).
It was therefore felt necessary to study the immune
response of different mouse strains to SRBC, SSS-IXI and
BSA under experimental conditions that would permit a
meaningful interstrain comparison.
Mice of strains listed in Table 1 were immunized with
a suboptimal dose of SRBC (3 x 107), SSS-III (0.1 ug.) and
BSA (0.1 rag.). In certain experiments mice were also
immunized with 1.0 rag. BSA. In all experiments only male
mice of comparable age were used. The mode of antigen
administration and the assay procedures for measuring immune
responses against different antigens were identical with
those described in detail in the early parts of this thesis.
The results recorded in Tables kl-k3 clearly exhibit
an interstrain variation in the response of mice tested to



























































































































































table 43 - immune response of different mouse strains
TO BOVINE SERUM ALBUMIN (BSA)a
Mouse
Strain
























































(a) 0.1 or 1.0 mg. BSA (alum precipitated) injected i.p.
on day O and tested on day 20.
(b) Geometric mean with the limits of one standard error.
(c) Arithmetic mean _+ 1 standard error.
(d) Number of mice per group.
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PPC response againat SRBC it is apparent that C57BI, A/HeJ
and C^H mice respond poorly to this antigen, whereas
nalb/c, CBA and DBA/1 mice give relatively high responses
(Table kl). This is also illustrated by the number of
EFC responses per 10^ nucleated spleen cells in different
strains summarized in Figure 23. Incidentally, the
closed circles in Figures 23-26 represent the responses
of individual mice .
The strain variations in the immune response to SSS-III
followed a pattern somewhat similar to that of anti-SRBC
response with the exception of DBA/1 and C^H mice. It
is apparent that A/lieJ, C57BI and DBA/1 mice always responded
poorly whereas Balb/o mice responded favourably to this
antigen. It should be noted that C3H mice which responded
poorly compared with CBA mice when tested against SRBC gave
an anti-SSS-III response which was comparable to that in
CBA mice. It should also be noted that DBA/1 mice which
gave a favourable anti-SRBC response failed to give an
anti-SSS-III response comparable to that observed in
Balb/c mice (Figure 2k).
The pattern of interstrain variations in the responsive¬
ness of mice tested against BSA was grosslydifferent from
that obtained with SRBC or SSS-III. However it is interesting
to note that C37BI mice still failed to respond favourably
to this antigen (Table k3 and Figures 25 and 26). A/HeJ
























































antigens appeared to be the best responders to BSA, whereas
Balb/c mice which were the best responders against SRBC
and SSS-XXX gave only a poor to moderate response against
USA. Xt should be noted that the interstrain variations
in the responsiveness to this antigen were more distinct
in mice challenged with the lower antigen dose (0.1 mg.(
Figure 26). It is apparent that when 1 rag. BSA was
administered Balb/c, DBA/1, CBA and CjH mice gave comparable
responses which were between the extreme responses given
by A/HeJ and C57BI mice (Figure 26).
The results of relative binding affinity determinations
did not in any way correlate with the responsiveness of
different mouse strains (Figure 27). However, striking
differences were noticed in the relative binding affinities
of anti-BSA antibodies produced by different strains.
Quantitative differences in the ability of different
mouse strains to respond to SKBC (Stern, Brown and Davidsohn,
1956t Playfair, 1968) Buscbman, Krausslich, Meyer,
Kadzikowski and Osterkorn, 1972), bacterial polysaccharides
(Braley and Freeman, 1971; DiFauli, 1972; Braun, Kindred
and Jacobson, 1972) and other protein, polysaccharide and
poly-amino acid antigens (McOevitt and Chinitz, 1969t McDevitt
and Benacerraf, 1969; Cerottlni, Lambert and Dixon, 1969;
Vaz, Vaz and Levins, 1970; Lieberman and Humphrey, 1972)
have been reported. the findings documented here generally




































































responsiveness of C^Bl mice and the hyper-responsiveness
of Balb/c mice to SRBC is in general agreement with the
findings of Playfair (1968).
Similarly the variations in the responsiveness of
different mice against SSS-XX1 are consistent with the
findings previously reported by Braley and Freeman (1972)*
Thus, Balb/c mice gave the highest response to this antigen,
whereas the response of C^Bl and A/HeJ mice was extremely
low. However, in contrast to their findings indicating
a difference in the responsiveness of CBA and C3H mice
(the former being the poorer of the two) the results
reported here indicated a comparable response in the two
mouse strains (Figure 2k).
The variations in the responsiveness of different
strains is more striking in experiments with BSA (Figure 25)
although these differences are relatively less marked in mice
challenged with the higher antigen dose (Figure 2b). These
results are in agreement with those of Cerottini, Lambert
and Dixon (1969) in as much as the hyper-responsiveness of
A/HeJ mice is concerned. However in contrast with the
findings recorded here Cerottini and his colleagues found
that CBA mice responded poorly in comparison with Balb/c
mice. This difference may however be due to the modification
of the immune response of one or both the mouse strains by
the use of Freund's complete adjuvant by these authors
(Cerottini, Lambert and Dixon, 1969).
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In addition* the affinities of anti-BSA antibody
produced varied from strain to strain (Figure 27)• It
is interesting to note that similar interstrain variations
in the affinity of anti-BSA antibody have been previously
reported (Soothill and Steward* 1971} Petty, Steward
and Soothill* 1972). However* these results contrast
with those of Cerottini and his colleagues who failed
to notice any interstrain variations in the relative
binding affinity of anti-BSA antibody produced by different
mouse strains (Cerottini* Lambert and Dixon* 1969). This
could perhaps again be due to the use of Freund*s complete
adjuvant in their experiments* Xt should be noted that
there was no correlation between the responsiveness of
different mouse strains and the affinity of antibody
produced. Thus* CBA and C3H mice which responded com¬
parably to BSA did not produce antibodies of the same
relative binding affinity (see Figure 27)*
In several previous reports it has been shown that
strains of mice which are hypo-responsive to one antigen*
may exhibit normal or enhanced response to other antigens.
Thus* Playfair (1968) observed that although NZB mice
responded favourably to SRBC compared with Balb/c mice,
the two strains gave comparable responses against pig and
chicken erythrocytes. Nevertheless, he too found that
C37BI mice were unable to respond favourably to any of
the antigens he tested. Similarly* McDevitt and Chinitz
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(1969) showed that mice which responded poorly to (H,G)-A-L
gave a good response to (T.G)-A-L and (Phe,G)-A-L and those
which responded well to (Phe,G)-A-L gave only a meagre
response to (T,G)-A-L and (H,G)-A-L. This pattern in
the responsiveness of different mouse strains to various
antigens has been noted by others (cerottini, Lambert and
Dixon, 1969)*
The findings reported here generally confirm the
observations referred to above. For example, A/HeJ mice
which produced the best response against BSA gave very
poor responses against SRBC and SSS-III. Conversely,
Balb/c mice which gave the highest responses against SRBC
and SSS-IZI produced only a modest response against BSA.
In addition DBA/1 mice which were as good as Balb/c mice
in their anti-SRBC response did not give an anti-SSS-XXI
response comparable with Balb/c mice. It is however
interesting to note that C57BI mice remained throughout
the poorest responders to all three antigens. It should
be recalled that this mouse strain has been reported to
give a very poor response to several other antigens (Playfair,
1963{ Braun, Kindred and Jacobsen, 1972).
Finally, a relationship between histocompatibility
(H—2) genotype and the responsiveness to different antigens
has been repeatedly reported (McDevitt and Benaceraff, 1969:
Skarova and Riha, 1969: Gaeser, 1969: Tyan, McDevitt and
Herzenberg, 1969: McDevitt and Chinitz, 1969: Vaz, Vaz
-135-
and Levine, 1970). However, from the studies reported here
it is not possible to conclude whether or not the responsive¬
ness to different antigens is related to the H-2 genotype,
although there is some suggestion that it may be so.
This is reflected by the comparable responsiveness of C3H
and CBA (both U—2**) mice to SSS-III and BSA. In contrast,
the response of these two strains did not appear to be
comparable when challenged with SRBC. This may be due
to the complex nature of the latter antigen. It should,
however, again be stressed that the data from experiments
reported here are not adequate enough to draw any conclusions
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